Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 45
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

Assessment of school anti-bullying interventions: A Meta-analysis of randomized clinical trials

  • Fraguas Herráez, David
  • Díaz Caneja, Covadonga M.
  • Ayora, Miriam
  • Durán Cutilla, Manuel
  • Abregú Crespo, Renzo
  • Ezquiaga Bravo, Iciar
  • Martín Babarro, Javier
  • Arango López, Celso
Importance: Bullying is a prevalent and modifiable risk factor for mental health disorders. Although previous studies have supported the effectiveness of anti-bullying programs; their population impact and the association of specific moderators with outcomes are still unclear. Objective: To assess the effectiveness of school anti-bullying interventions, their population impact, and the association between moderator variables and outcomes. Data Sources: A search of Ovid MEDLINE, ERIC, and PsycInfo databases was conducted using 3 sets of search terms to identify randomized clinical trials (RCTs) assessing anti-bullying interventions published from database inception through February 2020. A manual search of reference lists of articles included in previous systematic reviews and meta-analyses was also performed. Study Selection: The initial literature search yielded 34 798 studies. Included in the study were articles that (1) assessed bullying at school; (2) assessed the effectiveness of an anti-bullying program; (3) had an RCT design; (4) reported results; and (5) were published in English. Of 16 707 studies identified, 371 met the criteria for review of full-text articles; 77 RCTs were identified that reported data allowing calculation of effect sizes (ESs). Of these, 69 independent trials were included in the final meta-analysis database. Data Extraction and Synthesis: Random-effects and meta-regression models were used to derive Cohen d values with pooled 95% CIs as estimates of ES and to test associations between moderator variables and ES estimates. Population impact number (PIN), defined as the number of children in the total population for whom 1 event may be prevented by an intervention, was used as an estimate of the population impact of universal interventions targeting all students, regardless of individual risk. Main Outcomes and Measures: The main outcomes are the effectiveness (measured by ES) and the population impact (measured by the PIN) of anti-bullying interventions on the following 8 variable categories: Overall bullying, bullying perpetration, bullying exposure, cyberbullying, attitudes that discourage bullying, attitudes that encourage bullying, mental health problems (eg, anxiety and depression), and school climate as well as the assessment of potential assocations between trial or intervention characteristics and outcomes. Results: This study included 77 samples from 69 RCTs (111659 participants [56511 in the intervention group and 55148 in the control group]). The weighted mean (range) age of participants in the intervention group was 11.1 (4-17) years and 10.8 (4-17) years in the control group. The weighted mean (range) proportion of female participants in the intervention group was 49.9% (0%-100%) and 50.5% (0%-100%) in the control group. Anti-bullying interventions were efficacious in reducing bullying (ES,-0.150; 95% CI,-0.191 to-0.109) and improving mental health problems (ES,-0.205; 95% CI,-0.277 to-0.133) at study end point, with PINs for universal interventions that target the total student population of 147 (95% CI, 113-213) and 107 (95% CI, 73-173), respectively. Duration of intervention was not statistically significantly associated with intervention effectiveness (mean [range] duration of interventions, 29.4 [1 to 144] weeks). The effectiveness of anti-bullying programs did not diminish over time during follow-up (mean [range] follow-up, 30.9 [2-104] weeks). Conclusions and Relevance: Despite the small ESs and some regional differences in effectiveness, the population impact of school anti-bullying interventions appeared to be substantial. Better designed trials that assess optimal intervention timing and duration are warranted.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

La psiquiatría post-COVID-19

  • Vieta, Eduard
  • Pérez Solà, Víctor
  • Arango, Celso
EV would like to thank the Ministry of Science and Research (PI15/00283, PI18/00805) integrated in the National R+D+I Plan and co-financed by the ISCIII-General Subdirectorate of Evaluation and the European Regional Development Fund (ERDF), the Commission for Universities and Research, Department of Innovation, Universities, and Business (DIUE), Government of Catalonia (2017 SGR 1365), and project SLT006/17/00357 of the Strategic Plan for Health Research and Innovation (PERIS) 2016–2020 (Department of Health), CERCA PROGRAM, Government of Catalonia. VP would like to thank the Ministry of Science and Research (PI19/00236) integrated in the National R+D+I Plan and co-financed by the ISCIII-General Subdirectorate of Evaluation and the European Regional Development Fund (ERDF), CIBERSAM G21. Commission for Universities and Research, Department of Innovation, Universities, and Business (DIUE), Government of Catalonia (2017 SGR 134), CERCA Program, Government of Catalonia. CA has received support from the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by the European Commission's ERDF Fund, “A way of making Europe,” CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No. 115916, Project PRISM, and grant agreement No. 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, and Fundación Alicia Koplowitz.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Neonatal brain dynamic functional connectivity in term and preterm infants and its association with early childhood neurodevelopment

  • França, Lucas G. S.
  • Deco, Gustavo
  • Batalle, Dafnis
Brain dynamic functional connectivity characterises transient connections between brain regions. Features of brain dynamics have been linked to emotion and cognition in adult individuals, and atypical patterns have been associated with neurodevelopmental conditions such as autism. Although reliable functional brain networks have been consistently identified in neonates, little is known about the early development of dynamic functional connectivity. In this study we characterise dynamic functional connectivity with functional magnetic resonance imaging (fMRI) in the first few weeks of postnatal life in term-born (n = 324) and preterm-born (n = 66) individuals. We show that a dynamic landscape of brain connectivity is already established by the time of birth in the human brain, characterised by six transient states of neonatal functional connectivity with changing dynamics through the neonatal period. The pattern of dynamic connectivity is atypical in preterm-born infants, and associated with atypical social, sensory, and repetitive behaviours measured by the Quantitative Checklist for Autism in Toddlers (Q-CHAT) scores at 18 months of age. © The Author(s) 2024., This work was supported by the European Research Council under the European Union's Seventh Framework Programme (FP7/20072013)/ERC grant agreement no. 319456 (dHCP project) and a Wellcome Trust Seed Award in Science [217316/Z/19/Z] to DB. This study represents independent research part funded by the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King's College London. The authors also acknowledge support in part from the Engineering and Physical Sciences Research Council (EPSRC) Centre for Medical Engineering at Kings College London [WT 203148/Z/16/Z], MRC strategic grant [MR/K006355/1], the Department of Health through an NIHR Comprehensive Biomedical Research Centre Award (to King's College Hospital NHS Foundation Trust). The results leading to this publication have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777394 for the project AIMS-2-TRIALS. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI. S.F.M. and O.G.G. were supported by grants from the UK Medical Research Council [MR/N013700/1] and [MR/P502108/1] respectively. J.O.M., T.A., G.M., and A.D.E. received support from the Medical Research Council Centre for Neurodevelopmental Disorders, King's College London [MR/N026063/1]. L.C.-G. received support from Project PID2021-129022OA-I00 funded by MCIN/AEI/10.13039/501100011033/FEDER, EU, and CAM-Spain under the line support for R&D projects for Beatriz Galindo researchers BGP18/00178. J.J.T. was supported by grants from the Finnish Medical Foundation, Sigrid Juselius Foundation, Signe and Ane Gyllenberg Foundation, Emil Aaltonen Foundation and Hospital District of Southwest Finland State Research Grants. J.O.M. is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society [206675/Z/17/Z]. T.A. is supported by an MRC Clinician Scientist Fellowship [MR/P008712/1] and Transition Support Award [MR/V036874/1]. The authors acknowledge use of the research computing facility at King's College London, Rosalind (https://rosalind.kcl.ac.uk), which is delivered in partnership with the National Institute for Health Research (NIHR) Biomedical Research Centres at South London & Maudsley and Guy's & St. Thomas' NHS Foundation Trusts, and part-funded by capital equipment grants from the Maudsley Charity (award 980) and Guy's & St. Thomas' Charity (TR130505). The views expressed are those of the authors and not necessarily those of the funders, the NHS, the National Institute for Health Research, the Department of Health and Social Care, or the IHI-JU2. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis

  • Solanes, Aleix
  • Mezquida, Gisela
  • Janssen, Joost
  • Amoretti, Silvia
  • Lobo, Antonio
  • González-Pinto, Ana
  • Arango, Celso
  • Vieta, Eduard
  • Castro-Fornieles, Josefina
  • Bergé, Daniel
  • Albacete, Auria
  • Giné, Eloi
  • Parellada, Mara
  • Bernardo, Miquel
  • PEPs Group
  • Pomarol-Clotet, Edith
  • Radua, Joaquim
Detecting patients at high relapse risk after the first episode of psychosis (HRR-FEP) could help the clinician adjust the preventive treatment. To develop a tool to detect patients at HRR using their baseline clinical and structural MRI, we followed 227 patients with FEP for 18-24 months and applied MRIPredict. We previously optimized the MRI-based machine-learning parameters (combining unmodulated and modulated gray and white matter and using voxel-based ensemble) in two independent datasets. Patients estimated to be at HRR-FEP showed a substantially increased risk of relapse (hazard ratio = 4.58, P < 0.05). Accuracy was poorer when we only used clinical or MRI data. We thus show the potential of combining clinical and MRI data to detect which individuals are more likely to relapse, who may benefit from increased frequency of visits, and which are unlikely, who may be currently receiving unnecessary prophylactic treatments. We also provide an updated version of the MRIPredict software., We are grateful to all participants. We would also like to thank the Instituto de Salud Carlos III, the Spanish Ministry of Science, Innovation, and Universities, the European Regional Development Fund (ERDF/FEDER), European Social Fund, “Investing in your future”, “A way of making Europe” (projects: PI08/0208, PI11/00325, PI14/00292, PI14/00612, PI14/01148, PI14/01151, PI17/00481, PI17/01997, PI18/01055, PI19/00394, PI19/00766, PI20/00721, PI20/01342, and PI21/00713; contracts: CP14/00041, JR19/00024, CPII19/00009, and CD20/00177); CERCA Program; Catalan Government, the Secretariat of Universities and Research of the Department of Enterprise and Knowledge (2017SGR01271, 2017SGR1355, and 2017SGR1365); Institut de Neurociències, Universitat de Barcelona; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2); the University of the Basque Country (2019 321218ELCY GIC18/107); the Basque Government (2017111104); European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña. The funding organizations played no role in the study design, data collection, analysis, or manuscript approval.
Digibug. Repositorio Institucional de la Universidad de Granada
Publication Artículo científico (JournalArticle)

Does our cognitive empathy diminish with age? The moderator role of educational level

  • Gutiérrez Cobo, María José
  • Cabello González, Rosario
SB-C was funded by the Autism Research Trust, the Wellcome Trust, the Templeton World Charitable Foundation, and the NIHR Biomedical Research Centre in Cambridge, during the period of this work. SB-C received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 777394. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI. The research conducted by SB-C was supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care East of England at Cambridgeshire and Peterborough NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, NIHR, or Department of Health and Social Care., Introduction: The literature has demonstrated how the relationship between cognitive or emotional intelligence and age exhibits an inverted-U-shape and that this decline can be mitigated by an individual’s cognitive reserve (CR). Rather less is known, however, about the pattern of changes in cognitive empathy or the ability to recognize the thoughts or feelings of others. Objectives: The aim of the present study was firstly to analyze the effect of age, gender, and CR (measured through educational level), on the capacity to show cognitive empathy. Secondly, we aimed to evaluate what type of relationship—linear or quadratic—exists between age and cognitive empathy. We finally aimed to analyze the moderator role of educational level on the relationship between age and cognitive empathy. Participants: Totally, 902 Spanish adults aged between 18 and 79 years (M= 43.53, SD = 11.86; 57% women). Measurements: Participants were asked to indicate their educational level (primary, high school, or college education) and their cognitive empathy was assessed using the Eyes test. Results: Women scored higher than men on cognitive empathy. Participants with a college education had higher scores on cognitive empathy than those with a lower educational level. Additionally, the relationship between age and cognitive empathy fit an inverted-U-shaped curve, consistent with the data found for cognitive and emotional intelligence. Finally, the age-related decrease in cognitive empathy appeared to be mitigated by a higher educational level, but only in those individuals aged 35 years and above. Limitations and clinical implications are discussed., Autism Research Trust, Wellcome Trust, Templeton World Charitable Foundation, NIHR Biomedical Research Centre in Cambridge, Innovative Medicines Initiative 2 Joint Undertaking (JU) 777394, European Commission, EFPIA, AUTISM SPEAKS, Autistica, SFARI, National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care East of England at Cambridgeshire and Peterborough NHS Foundation Trust
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis.

  • Solanes Font, Aleix
  • Mezquida, Gisela
  • Janssen, Joost
  • Amoretti, Silvia
  • Lobo, Antonio
  • González Pinto Arrillaga, Ana María
  • Arango, Celso
  • Vieta, Eduard
  • Castro Fornieles, Josefina
  • Bergé, Daniel
  • Albacete, Auria
  • Giné, Eloi
  • Parellada, Mara
  • Bernardo, Miguel
  • PEPs Group
  • Pomarol Clotet, Edith
  • Radua, Joaquim
Detecting patients at high relapse risk after the first episode of psychosis (HRR-FEP) could help the clinician adjust the preventive treatment. To develop a tool to detect patients at HRR using their baseline clinical and structural MRI, we followed 227 patients with FEP for 18-24 months and applied MRIPredict. We previously optimized the MRI-based machine-learning parameters (combining unmodulated and modulated gray and white matter and using voxel-based ensemble) in two independent datasets. Patients estimated to be at HRR-FEP showed a substantially increased risk of relapse (hazard ratio=4.58, P<0.05). Accuracy was poorer when we only used clinical or MRI data. We thus show the potential of combining clinical and MRI data to detect which individuals are more likely to relapse, who may benefit from increased frequency of visits, and which are unlikely, who may be currently receiving unnecessary prophylactic treatments. We also provide an updated version of the MRIPredict software., We would also like to thank the Instituto de Salud Carlos III, the Spanish Ministry of Science, Innovation, and Universities, the European Regional Development Fund (ERDF/FEDER), European Social Fund, “Investing in your future”, “A way of making Europe” (projects: PI08/0208, PI11/00325, PI14/00292, PI14/00612, PI14/01148, PI14/01151, PI17/00481, PI17/01997, PI18/01055, PI19/00394, PI19/00766, PI20/00721, PI20/01342, and PI21/00713; contracts: CP14/00041, JR19/00024, CPII19/00009, and CD20/00177); CERCA Program; Catalan Government, the Secretariat of Universities and Research of the Department of Enterprise and Knowledge (2017SGR01271, 2017SGR1355, and 2017SGR1365); Institut de Neurociències, Universitat de Barcelona; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2); the University of the Basque Country (2019 321218ELCY GIC18/107); the Basque Government (2017111104); European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña. The funding organizations played no role in the study design, data collection, analysis, or manuscript approval.
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis

  • Molina García, Mariola
  • Fraguas, David
  • Del Rey Mejías, Ángel
  • Mezquida, Gisela
  • Sánchez Torres, Ana María
  • Amoretti, Silvia
  • Lobo, Antonio
  • González Pinto Arrillaga, Ana María
  • Andreu Bernabeu, Álvaro
  • Corripio, Iluminada
  • Vieta, Eduard
  • Baeza, Immaculada
  • Mané, Anna
  • Cuesta, Manuel
  • de la Serna, Elena
  • Payá, Beatriz
  • Zorrilla Martínez, Iñaki
  • Arango, Celso
  • Bernardo, Miquel
  • Rapado-Castro, Marta
  • Parellada, Mara
Background: premorbid IQ (pIQ) and age of onset are predictors of clinical severity and long-term functioning after a first episode of psychosis. However, the additive influence of these variables on clinical, functional, and recovery rates outcomes is largely unknown. Methods: we characterized 255 individuals who have experienced a first episode of psychosis in four a priori defined subgroups based on pIQ (low pIQ < 85; average pIQ ≥ 85) and age of onset (early onset < 18 years; adult onset ≥ 18 years). We conducted clinical and functional assessments at baseline and at two-year follow-up. We calculated symptom remission and recovery rates using the Positive and Negative Symptoms of Schizophrenia Schedule (PANSS) and the Global Assessment Functioning (GAF or Children-GAF). We examined clinical and functional changes with pair-wise comparisons and two-way mixed ANOVA. We built hierarchical lineal and logistic regression models to estimate the predictive value of the independent variables over functioning or recovery rates. Results: early-onset patients had more severe positive symptoms and poorer functioning than adult-onset patients. At two-year follow-up, only early-onset with low pIQ and adult-onset with average pIQ subgroups differed consistently, with the former having more negative symptoms (d = 0.59), poorer functioning (d = 0.82), lower remission (61% vs. 81.1%), and clinical recovery (34.1% vs. 62.2%). Conclusions: early-onset individuals with low pIQ may present persistent negative symptoms, lower functioning, and less recovery likelihood at two-year follow-up. Intensive cognitive and functional programs for these individuals merit testing to improve long-term recovery rates in this subgroup., This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III, PI02/1248, PI03032, PI05/0678, PI08/0208 PI09/01442, PI11/00325, PI12/1303, PI14/00612, PI15/00723, PI17/009977, PI18/00753 cofinanced by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2). The CERCA Program/Generalitat de Catalunya And Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement (2017SGR1355). Departament de Salut de la Generalitat de Catalunya, en la convocatoria corresponent a l’any 2017 de concessió de subvencions del Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020, modalitat Projectes de recerca orientats a l’atenció primària, amb el codi d’expedient SLT006/17/00345. European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTiMISE), FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña.
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia

  • Andreu-Bernabeu, Álvaro
  • Díaz Caneja, Covadonga
  • Costas, Javier
  • de Hoyos, Lucía
  • Stella, Carol
  • Gurriarán, Xaquín
  • Alloza, Clara
  • Fañanás, Lourdes
  • Bobes, Julio
  • González Pinto Arrillaga, Ana María
  • Crespo Facorro, Benedicto
  • Martorell, Lourdes
  • Vilella, Elisabet
  • Muntané, Gerard
  • Nacher, Juan
  • Moltó, María Dolores
  • Aguilar, Eduardo Jesús
  • Parellada, Mara
  • Arango, Celso
  • González Peñas, Javier
[EN] Previous research suggests an association of loneliness and social isolation (LNL-ISO) with schizophrenia. Here, we demonstrate a LNL-ISO polygenic score contribution to schizophrenia risk in an independent case-control sample (N=3,488). We then subset schizophrenia predisposing variation based on its effect on LNL-ISO. We find that genetic variation with concordant effects in both phenotypes shows significant SNP-based heritability enrichment, higher polygenic contribution in females, and positive covariance with mental disorders such as depression, anxiety, attention-deficit hyperactivity disorder, alcohol dependence, and autism. Conversely, genetic variation with discordant effects only contributes to schizophrenia risk in males and is negatively correlated with those disorders. Mendelian randomization analyses demonstrate a plausible bi-directional causal relationship between LNL-ISO and schizophrenia, with a greater effect of LNL-ISO liability on schizophrenia than vice versa. These results illustrate the genetic footprint of LNL-ISO on schizophrenia., This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, PI20/00721), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN), and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz, and Fundación Mutua Madrileña. We are grateful to Paloma Pantoja for her assistance in the design of the figures. A.A.-B. holds a Rio Hortega Grant from Instituto de Salud Carlos III (CM20/00114). C.M.D.-C. holds a Juan Rodés Grant from Instituto de Salud Carlos III (JR19/00024).
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Cortical thinning over two years after first-episode psychosis depends on age of onset.

  • Pina Camacho, Laura
  • Martínez, Kenia
  • Díaz Caneja, Covadonga
  • Mezquida, Gisela
  • Cuesta, Manuel J.
  • Moreno, Carmen
  • Amoretti, Silvia
  • González Pinto Arrillaga, Ana María
  • Arango, Celso
  • Vieta, Eduard
  • Castro Fornieles, Josefina
  • Lobo, Antonio
  • Fraguas, David
  • Bernardo, Miguel
  • Janssen, Joost
  • Parellada, Mara
  • Zorrilla Martínez, Iñaki
  • PEPs Group
[EN] First-episode psychosis (FEP) patients show structural brain abnormalities at the first episode. Whether the cortical changes that follow a FEP are progressive and whether age at onset modulates these changes remains unclear. This is a multicenter MRI study in a deeply phenotyped sample of 74 FEP patients with a wide age range at onset (15-35 years) and 64 neurotypical healthy controls (HC). All participants underwent two MRI scans with a 2-year follow-up interval. We computed the longitudinal percentage of change (PC) for cortical thickness (CT), surface area (CSA) and volume (CV) for frontal, temporal, parietal and occipital lobes. We used general linear models to assess group differences in PC as a function of age at FEP. We conducted post-hoc analyses for metrics where PC differed as a function of age at onset. We found a significant age-by-diagnosis interaction effect for PC of temporal lobe CT (d=0.54; p=002). In a post-hoc-analysis, adolescent-onset (≤19y) FEP showed more severe longitudinal cortical thinning in the temporal lobe than adolescent HC. We did not find this difference in adult-onset FEP compared to adult HC. Our study suggests that, in individuals with psychosis, CT changes that follow the FEP are dependent on the age at first episode, with those with an earlier onset showing more pronounced cortical thinning in the temporal lobe., We are extremely grateful to all subjects who took part in this study. This work was supported by CIBERSAM; Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (PI081203, PI08/0208; PI11/00325; PI1101686, PI14/00612, PI17/01997, PI20/01342), co‐financed by the ERDF from the European Commission “A way of making Europe”, European Union Seventh Framework Program (FP7- HEALTH-2013-2.2.1-2-603196 [Project PSYSCAN]), EU H2020 (IMI‐2 Joint Undertaking under grant agreements 115916 (project PRISM) and 777394 (project AIMS‐2‐TRIALS)), Madrid Regional Government (S2017/BMD‐3740, and AGES-CM-2-CM) and European Union Structural Funds; Fundación Familia Alonso, Fundacion Mutua Madrileña, and Fundación Alicia Koplowitz.
RUA. Repositorio Institucional de la Universidad de Alicante
Publication Otros (Other)

Subcellular sorting of neuregulins controls the assembly of excitatory-inhibitory cortical circuits

  • Exposito-Alonso, David
  • Osório, Catarina
  • Bernard, Clémence
  • Pascual-García, Sandra
  • del Pino, Isabel
  • Marín, Óscar
  • Rico, Beatriz
  • Pascual-García, Sandra|||/items/0b1ae2ac-a229-4bb2-b0a9-32342996babc
The assembly of specific neuronal circuits relies on the expression of complementary molecular programs in presynaptic and postsynaptic neurons. In the cerebral cortex, the tyrosine kinase receptor ErbB4 is critical for the wiring of specific populations of GABAergic interneurons, in which it paradoxically regulates both the formation of inhibitory synapses as well as the development of excitatory synapses received by these cells. Here, we found that Nrg1 and Nrg3, two members of the neuregulin family of trophic factors, regulate the inhibitory outputs and excitatory inputs of interneurons in the mouse cerebral cortex, respectively. The differential role of Nrg1 and Nrg3 in this process is not due to their receptor-binding EGF-like domain, but rather to their distinctive subcellular localization within pyramidal cells. Our study reveals a novel strategy for the assembly of cortical circuits that involves the differential subcellular sorting of family-related synaptic proteins.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia

  • Andreu-Bernabeu, Álvaro
  • Díaz-Caneja, Covadonga M.
  • Costas, Javier
  • De Hoyos, Lucía
  • Stella, Carol
  • Gurriarán, Xaquín
  • Alloza, Clara
  • Fañanás Saura, Lourdes
  • Bobes García, Julio
  • González-Pinto, Ana
  • Crespo-Facorro, Benedicto
  • Martorell, Lourdes
  • Vilella, Elisabet
  • Muntané, Gerard
  • Nacher, Juan
  • Moltó, M. Dolors
  • Aguilar, Eduardo Jesús
  • Parellada, Mara
  • Arango López, Celso
  • González-Peñas, Javier
Previous research suggests an association of loneliness and social isolation (LNL-ISO) with schizophrenia. Here, we demonstrate a LNL-ISO polygenic score contribution to schizophrenia risk in an independent case-control sample (N = 3,488). We then subset schizophrenia predisposing variation based on its effect on LNL-ISO. We find that genetic variation with concordant effects in both phenotypes shows significant SNP-based heritability enrichment, higher polygenic contribution in females, and positive covariance with mental disorders such as depression, anxiety, attention-deficit hyperactivity disorder, alcohol dependence, and autism. Conversely, genetic variation with discordant effects only contributes to schizophrenia risk in males and is negatively correlated with those disorders. Mendelian randomization analyses demonstrate a plausible bi-directional causal relationship between LNL-ISO and schizophrenia, with a greater effect of LNL-ISO liability on schizophrenia than vice versa. These results illustrate the genetic footprint of LNL-ISO on schizophrenia.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Altered structural brain asymmetry in autism spectrum disorder in a study of 54 datasets

  • Postema, Merel C.
  • van Rooij, Daan
  • Anagnostou, Evdokia
  • Arango, Celso
  • Auzias, Guillaume
  • Behrmann, Marlene
  • Filho, Geraldo Busatto
  • Calderoni, Sara
  • Calvo Escalona, Rosa
  • Daly, Eileen
  • Deruelle, Christine
  • Di Martino, Adriana
  • Dinstein, Illan
  • Duran, Fabio Luis S.
  • Durston, Sarah
  • Ecker, Christine
  • Ehrlich, Stefan
  • Fair, Damien
  • Fedor, Jennifer
  • Feng, Xin
  • FitzGerald, Jackie
  • Floris, Dorothea L.
  • Freitag, Christine M.
  • Gallagher, Louise
  • Glahn, David C.
  • Gori, Ilaria
  • Haar, Shlomi
  • Hoekstra, Liesbeth
  • Jahanshad, Neda
  • Jalbrzikowski, Maria
  • Janssen, Joost
  • King, Joseph A.
  • Kong, Xiang-Zhen
  • Lázaro García, Luisa
  • Lerch, Jason P.
  • Luna, Beatriz
  • Martinho, Mauricio M.
  • McGrath, Jane
  • Medland, Sarah E.
  • Muratori, Filippo
Altered structural brain asymmetry in autism spectrum disorder (ASD) has been reported. However, findings have been inconsistent, likely due to limited sample sizes. Here we investigated 1,774 individuals with ASD and 1,809 controls, from 54 independent data sets of the ENIGMA consortium. ASD was significantly associated with alterations of cortical thickness asymmetry in mostly medial frontal, orbitofrontal, cingulate and inferior temporal areas, and also with asymmetry of orbitofrontal surface area. These differences generally involved reduced asymmetry in individuals with ASD compared to controls. Furthermore, putamen volume asymmetry was significantly increased in ASD. The largest case-control effect size was Cohen's d = -0.13, for asymmetry of superior frontal cortical thickness. Most effects did not depend on age, sex, IQ, severity or medication use. Altered lateralized neurodevelopment may therefore be a feature of ASD, affecting widespread brain regions with diverse functions. Large-scale analysis was necessary to quantify subtle alterations of brain structural asymmetry in ASD.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis

  • Molina García, Mariola
  • Fraguas, David
  • Del Rey Mejias, Angel
  • Mezquida Mateos, Gisela
  • Sánchez-Torres, Ana M.
  • Amoretti Guadall, Silvia
  • Lobo, Antonio
  • González-Pinto, Ana
  • Andreu-Bernabeu, Álvaro
  • Corripio, Iluminada
  • Vieta i Pascual, Eduard, 1963-
  • Baeza, Inmaculada, 1970-
  • Mané Santacana, Anna
  • Cuesta, Manuel J.
  • Serna, Elena de la, 1978-
  • Payá, Beatriz
  • Zorrilla, Iñaki
  • Arango, Celso
  • Bernardo Arroyo, Miquel
  • Rapado-Castro, Marta
  • Parellada, Mara
  • PEPs Group
Background: premorbid IQ (pIQ) and age of onset are predictors of clinical severity and long-term functioning after a first episode of psychosis. However, the additive influence of these variables on clinical, functional, and recovery rates outcomes is largely unknown. Methods: we characterized 255 individuals who have experienced a first episode of psychosis in four a priori defined subgroups based on pIQ (low pIQ < 85; average pIQ ≥ 85) and age of onset (early onset < 18 years; adult onset ≥ 18 years). We conducted clinical and functional assessments at baseline and at two-year follow-up. We calculated symptom remission and recovery rates using the Positive and Negative Symptoms of Schizophrenia Schedule (PANSS) and the Global Assessment Functioning (GAF or Children-GAF). We examined clinical and functional changes with pair-wise comparisons and two-way mixed ANOVA. We built hierarchical lineal and logistic regression models to estimate the predictive value of the independent variables over functioning or recovery rates. Results: early-onset patients had more severe positive symptoms and poorer functioning than adult-onset patients. At two-year follow-up, only early-onset with low pIQ and adult-onset with average pIQ subgroups differed consistently, with the former having more negative symptoms (d = 0.59), poorer functioning (d = 0.82), lower remission (61% vs. 81.1%), and clinical recovery (34.1% vs. 62.2%). Conclusions: early-onset individuals with low pIQ may present persistent negative symptoms, lower functioning, and less recovery likelihood at two-year follow-up. Intensive cognitive and functional programs for these individuals merit testing to improve long-term recovery rates in this subgroup.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mapping genomic loci implicates genes and synaptic biology in schizophrenia

  • Trubetskoy, Vassily
  • Pardiñas, Antonio F.
  • Qi, Ting
  • Panagiotaropoulou, Georgia
  • Awasthi, Swapnil
  • Bigdeli, Tim B.
  • Bryois, Julien
  • Chen, Chia-Yen
  • Dennison, Charlotte A.
  • Hall, Lynsey S.
  • Lam, Max
  • Curtis, Charles
  • Nikitina-Zake, Liene
  • Davidson, Michael
  • Joa, Inge
  • Davis, Kenneth L.
  • Yolken, Robert
  • Murray, Robin M.
  • de Haan, Lieuwe
  • Legge, Sophie E.
  • Serretti, Alessandro
  • van Os, Jim
  • Smoller, Jordan W.
  • Agartz, Ingrid
  • Alizadeh, Behrooz Z.
  • Degenhardt, Franziska
  • DeLisi, Lynn E.
  • Demontis, Ditte
  • Dickerson, Faith
  • Zai, Clement C.
  • Dikeos, Dimitris
  • Dinan, Timothy
  • Henskens, Frans A.
  • Vaaler, Arne
  • Noto, Cristiano
  • Nimgaonkar, Vishwajit
  • Rautanen, Anna
  • Lehrer, Douglas S.
  • Djurovic, Srdjan
  • Duan, Jubao
  • Julià, Antonio
  • Stahl, Eli A.
  • Zhou, Wei
  • Vawter, Marquis P.
  • Toncheva, Draga
  • Webb, Bradley T.
  • Ducci, Giuseppe
  • Dudbridge, Frank
  • Eriksson, Johan G.
  • Fañanas Saura, Lourdes
  • Goldstein, Jacqueline I.
  • Faraone, Stephen V.
  • Lencer, Rebecca
  • Moreno, Carmen
  • Bacanu, Silviu A.
  • Fiorentino, Alessia
  • Calkins, Monica E.
  • Mitjans, Marina
  • Forstner, Andreas
  • Nuechterlein, Keith H.
  • Frank, Josef
  • Tsuang, Debby W.
  • Freimer, Nelson B.
  • Tooney, Paul A.
  • Belangero, Sintia Iole
  • Weinberger, Daniel R.
  • Fromer, Menachem
  • Ge,Tian
  • Adolfsson, Rolf
  • Hakonarson, Hakon
  • Zhu, Feng
  • Frustaci, Alessandra
  • Nöthen, Markus M.
  • Gadelha, Ary
  • Genovese, Giulio
  • Gershon, Elliot S.
  • Quattrone, Diego
  • Kähler, Anna K.
  • Kam-Thong, Tony
  • van Amelsvoort, Therese
  • Vilella, Elisabet
  • Molden, Espen
  • O'Brien, Niamh Louise
  • Zimprich, Fritz
  • Kamatani, Yoichiro
  • Braun, Alice
  • Melegh, Bela
  • Pirinen, Matti
  • Karachanak-Yankova, Sena
  • Ophoff, Roel A.
  • Kebir, Oussama
  • Lerer, Bernard
  • Nordentoft, Merete
  • Fanous, Ayman H.
  • Reichenberg, Abraham
  • Li, Miaoxin
  • Periyasamy, Sathish
  • Lieberman, Jeffrey
  • Werge, Thomas
  • Light, Gregory A.
  • Limborska, Svetlana
  • Tosato, Sarah
  • Liu, Chih-Min
  • Olincy, Ann
  • Magnusson, Sigurdur
  • Gareeva, Anna
  • Bressan, Rodrigo Affonseca
  • Lönnqvist, Jouko
  • Roe, Cheryl
  • Cheng, Wei
  • Athanasiu, Lavinia
  • Gutiérrez, Blanca
  • Harvey, Carol
  • Loughland, Carmel M.
  • Lubinski, Jan
  • Luykx, Jurjen J.
  • Lynham, Amy
  • Gawlik, Micha
  • Macek, Milan
  • Mackinnon, Andrew
  • Buxbaum, Joseph D.
  • Tura, Gian Battista
  • Bromet, Evelyn J.
  • Atbaşoğlu, Eşref Cem
  • Roffman, Joshua L.
  • Magnusson, Patrik K. E.
  • Maher, Brion S.
  • Ota, Vanessa Kiyomi
  • Paciga, Sara A.
  • Gejman, Pablo V.
  • Arango, Celso
  • Forti, Marta Di
  • Maier, Wolfgang
  • Richards, Alexander L.
  • Malaspina, Dolores
  • Mallet, Jacques
  • Metspalu, Andres
  • Marder, Stephen R.
  • Li, Zhiqiang
  • Takahashi, Atsushi
  • Marsal, Sara
  • Kučinskiene, Zita Ausrele
  • Suvisaari, Jaana
  • Martin, Alicia R.
  • Turetsky, Bruce I.
  • Martorell, Lourdes
  • Palotie, Aarno
  • Mattheisen, Manuel
  • Baune, Bernhard T.
  • Saka, Meram C.
  • McCarley, Robert W.
  • Giusti-Rodríguez, Paola
  • Riley, Brien P.
  • Murphy, Kieran C.
  • Gill, Michael
  • McDonald, Colm
  • Bruggeman, Richard
  • McGrath, John J.
  • Sidorenko, Julia
  • Medeiros, Helena
  • Pantelis, Christos
  • Grove, Jakob
  • Campion, Dominique
  • Pato, Carlos N.
  • Svrakic, Dragan M.
  • Üçok, Alp
  • Glatt, Stephen J.
  • Papadimitriou, George N.
  • Khrunin, Andrey
  • Straub, Richard E.
  • Parellada, Mara
  • Buckley, Peter F.
  • Paunio, Tiina
  • Roth, Julian
  • Morgan, Vera A.
  • Wildenauer, Dieter B.
  • Ayub, Muhammad
  • Rothermundt, Matthias
  • Weiser, Mark
  • Rutten, Bart P. F.
  • Saker-Delye, Safaa
  • Salomaa, Veikko
  • Børglum, Anders D.
  • Sanjuán, Julio
  • van Winkel, Ruud
  • González Peñas, Javier
  • Yu, Xin
  • Kim, Sung-Wan
  • Santoro, Marcos Leite
  • Benner, Christian
  • Ikeda, Masashi
  • Morley, Christopher P.
  • Zeng, Jian
  • Savitz, Adam
  • Schall, Ulrich
  • Scott, Rodney J.
  • Voloudakis, Georgios
  • Yue, Weihua
  • Seidman, Larry J.
  • Sharp, Sally Isabel
  • Alptekin, Köksal
  • Klovins, Janis
  • Amin, Farooq
  • Bertolino, Alessandro
  • Shi, Jianxin
  • Siever, Larry J.
  • Atkinson, Elizabeth G.
  • Buckner, Randy L.
  • Holmans, Peter A.
  • Rivera, Margarita
  • Sigurdsson, Engilbert
  • González-Pinto, Ana
  • Sim, Kang
  • Skarabis, Nora
  • Stroup, T Scott
  • Slominsky, Petr
  • Guillin, Olivier
  • Wang, Shi-Heng
  • So, Hon-Cheong
  • Quested, Digby
  • Sobell, Janet L.
  • Braff, David
  • Zhang, Wen
  • Bybjerg-Grauholm, Jonas
  • Söderman, Erik
  • Rujescu, Dan
  • Chambert, Kimberley D.
  • Stain, Helen J.
  • Melle, Ingrid
  • Carr, Vaughan J.
  • Pocklington, Andrew J.
  • Steen, Nils Eiel
  • Harwood, Janet
  • Steixner-Kumar, Agnes A.
  • Gopal, Srihari
  • Stögmann, Elisabeth
  • Veijola, Juha
  • Watanabe, Kyoko
  • Sham, Pak C.
  • Cahn, Wiepke
  • Bramon, Elvira
  • Roussos, Panos
  • Waddington, John
  • Perkins, Diana O.
  • Pato, Michele T.
  • Walter, Henrik
  • Kondratiev, Nikolay
  • Waterreus, Anna
  • Al Eissa, Mariam
  • Bobes, Julio
  • Golimbet, Vera
  • Black, Donald W.
  • Als, Thomas D.
  • Bray, Nicholas J.
  • Breen, Gerome
  • Buccola, Nancy G.
  • Sanders, Alan R.
  • Byerley, William F.
  • Cervilla, Jorge A.
  • Michie, Patricia T.
  • Pfuhlmann, Bruno
  • Chen, Wei J.
  • Hong, Kyung Sue
  • O'Neill, F Anthony
  • Terao, Chikashi
  • Green, Michael F.
  • Cloninger, C. Robert
  • Crespo-Facorro, Benedicto
  • Donohoe, Gary
  • Gülöksüz, Sinan
  • Freedman, Robert
  • Albus, Margot
  • Hayward, Caroline
  • Pietiläinen, Olli
  • Herms, Stefan
  • Hultman, Christina M.
  • Galletly, Cherrie
  • Gandal, Michael J.
  • Hahn, Eric
  • Konte, Bettina
  • Castle, David
  • Gennarelli, Massimo
  • Milani, Lili
  • Hougaard, David M.
  • Hwu, Hai-Gwo
  • Pulver, Ann E.
  • Jablensky, Assen V.
  • Molina, Esther
  • Qin, Shengying
  • McCarroll, Steven A.
  • Moran, Jennifer L.
  • Azevedo, Maria Helena
  • Gur, Rachel E.
  • Kraft, Julia
  • Mors, Ole
  • Catts, Stanley V.
  • Lazzeroni, Laura C.
  • Mortensen, Preben B.
  • Streit, Fabian
  • Kusumawardhani, Agung
  • Alexander, Madeline
  • Godard, Stephanie
  • Müller-Myhsok, Bertram
  • Milanova, Vihra
  • Neil, Amanda L.
  • Cichon, Sven
  • Giannitelli, Marianna
  • Cheung, Eric F. C.
  • Kubo, Michiaki
  • Schwab, Sibylle G.
  • Collier, David A.
  • Williams, Nigel M.
  • Morris, Derek W.
  • Corvin, Aiden
  • Pimm, Jonathan
  • Curtis, David
  • Haroutunian, Vahram
  • Keller, Matthew C.
  • Vassos, Evangelos
  • Hyman, Steven E.
  • Iwata, Nakao
  • Jönsson, Erik G.
  • Kahn, René S.
  • Chan, Raymond C. K.
  • Kennedy, James L.
  • Shi, Yongyong
  • Adams, Mark
  • Witt, Stephanie H.
  • Khusnutdinova, Elza
  • Verhage, Matthijs
  • Xu, Shuhua
  • Wu, Yang
  • Kirov, George
  • Arolt, Volker
  • Knowles, James A.
  • Moltó, Maria Dolores
  • Krebs, Marie-Odile
  • Hartmann, Annette M.
  • Nestadt, Gerald
  • Wormley, Brandon K.
  • Bass, Nicholas J.
  • Laurent-Levinson, Claudine
  • Lee, Jimmy
  • Muntané, Gerard
  • Porteous, David
  • Kuzelova-Ptackova, Hana
  • Lencz, Todd
  • Subramaniam, Mythily
  • Levinson, Douglas F.
  • Li, Qingqin S.
  • Liu, Jianjun
  • Swerdlow, Neal R.
  • Cairns, Murray J.
  • Malhotra, Anil K.
  • Malhotra, Dheeraj
  • Iyegbe, Conrad
  • Mondelli, Valeria
  • Kim, Minsoo
  • Arrojo, Manuel
  • Landi, Stefano
  • McIntosh, Andrew M.
  • Petryshen, Tracey L.
  • Radant, Allen D.
  • Frei, Oleksandr
  • Mesholam-Gately, Raquelle I.
  • McQuillin, Andrew
  • Sugar, Catherine A.
  • Menezes, Paulo Rossi
  • St Clair, David
  • Meier, Sandra
  • Powell, John
  • Chaumette, Boris
  • Stefansson, Hreinn
  • Domenici, Enrico
  • Bonassi, Stefano
  • Stefánsson, Kári
  • Wu, Jing Qin
  • Tsuang, Ming T.
  • Myin-Germeys, Inez
  • Pellegrino, Renata
  • Visscher, Peter M.
  • Yang, Jian
  • Posthuma, Danielle
  • Andreassen, Ole A.
  • Koopmans, Frank
  • Kendler, Kenneth S.
  • Chong, Siow Ann
  • Gur, Ruben C.
  • Ehrenreich, Hannelore
  • Owen, Michael J.
  • Rietschel, Marcella
  • Gratten, Jacob
  • Wray, Naomi R.
  • Hoffmann, Per
  • Daly, Mark J.
  • Szatkiewicz, Jin P.
  • Huang, Hailiang
  • Nenadić, Igor
  • Torretta, Silvia
  • Escott-Price, Valentina
  • Neale, Benjamin M.
  • Begemann, Martin
  • Thibaut, Florence
  • Agerbo, Esben
  • Rampino, Antonio
  • Sullivan, Patrick F.
  • Schulze, Thomas G.
  • Ripke, Stephan
  • Walters, James T. R.
  • O'Donovan, Michael C.
  • Kučinskas, Vaidutis
  • Belliveau, Richard A.
  • Bene, Judit
  • Oh, Sang-Yun
  • Ta, Thi Minh Tam
  • Greenwood, Tiffany A.
  • Howrigan, Daniel P.
  • Rapaport, Mark H.
  • Benyamin, Beben
  • Mowry, Bryan J.
  • Giegling, Ina
  • Strengman, Eric
  • Bergen, Sarah E.
  • Silverman, Jeremy M.
  • Blasi, Giuseppe
  • Cohen, David
  • Stone, William S.
  • Xu, Zhida
  • Lee, Phil H.
  • Consoli, Angèle
  • Kelly, Brian
  • Cordeiro, Quirino
  • Esko, Tõnu
  • Costas, Javier
Schizophrenia has a heritability of 60-80%1, much of which is attributable to common risk alleles. Here, in a two-stage genome-wide association study of up to 76,755 individuals with schizophrenia and 243,649 control individuals, we report common variant associations at 287 distinct genomic loci. Associations were concentrated in genes that are expressed in excitatory and inhibitory neurons of the central nervous system, but not in other tissues or cell types. Using fine-mapping and functional genomic data, we identify 120 genes (106 protein-coding) that are likely to underpin associations at some of these loci, including 16 genes with credible causal non-synonymous or untranslated region variation. We also implicate fundamental processes related to neuronal function, including synaptic organization, differentiation and transmission. Fine-mapped candidates were enriched for genes associated with rare disruptive coding variants in people with schizophrenia, including the glutamate receptor subunit GRIN2A and transcription factor SP4, and were also enriched for genes implicated by such variants in neurodevelopmental disorders. We identify biological processes relevant to schizophrenia pathophysiology; show convergence of common and rare variant associations in schizophrenia and neurodevelopmental disorders; and provide a resource of prioritized genes and variants to advance mechanistic studies., The work at Cardiff University was additionally supported by Medical Research Council Centre grant no. MR/L010305/1 and program grant no. G0800509. S. Xu also gratefully acknowledges the support of the National Natural Science Foundation of China (NSFC) grants (31525014, 91731303, 31771388, 31961130380 and 32041008), the UK Royal Society-Newton Advanced Fellowship (NAF\R1\191094), the Key Research Program of Frontier Sciences (QYZDJ-SSW-SYS009) and the Strategic Priority Research Program (XDB38000000) of the Chinese Academy of Sciences, and the Shanghai Municipal Science and Technology Major Project (2017SHZDZX01). O. A. Andreassen was supported by the Research Council of Norway (283798, 262656, 248980, 273291, 248828, 248778, 223273); KG Jebsen Stiftelsen, South-East Norway Health Authority, EU H2020 no. 847776. B. Melegh was supported in part by the National Scientific Research Program (NKFIH) K 138669. S. V. Faraone is supported by the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no. 602805, the European Union’s Horizon 2020 research and innovation programme under grant agreements 667302 and 728018 and NIMH grants 5R01MH101519 and U01 MH109536-01. S. I. Belangero was supported by FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo), grant numbers: 2010/08968-6; 2014/07280-1 2011/50740-5 (including R. A. Bressan). The Singapore team (J. Lee, J. Liu, K. Sim, S. A. Chong and M. Subramanian) acknowledges the National Medical Research Council Translational and Clinical Research Flagship Programme (grant no.: NMRC/TCR/003/2008). M. Macek was supported by LM2018132, CZ.02.1.01/0.0/0.0/18_046/0015515 and IP6003 –VZFNM00064203. C. Arango has been funded by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement no 115916, project PRISM; and grant agreement no. 777394, project AIMS-2-TRIALS), Fundación Familia Alonso and Fundación Alicia Koplowitz. E. Bramon acknowledges support from the National Institute of Health Research UK (grant NIHR200756); Mental Health Research UK John Grace QC Scholarship 2018; an ESRC collaborative award 2020; BMA Margaret Temple Fellowship 2016; Medical Research Council New Investigator Award (G0901310); MRC Centenary Award (G1100583); MRC project grant G1100583; National Institute of Health Research UK post-doctoral fellowship (PDA/02/06/016); NARSAD Young Investigator awards 2005 and 2008; Wellcome Trust Research Training Fellowship; Wellcome Trust Case Control Consortium awards (085475/B/08/Z, 085475/Z/08/Z); European Commission Horizon 2020 (747429); NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and King’s College London; and NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London (UCLH BRC - Mental Health Theme). D. Molto is funded by the European Regional Development Fund (ERDF)–Valencian Community 2014–2020, Spain. E. G. Atkinson was supported by the NIMH K01MH121659., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Childhood Maltreatment, Educational Attainment, and IQ: Findings From a Multicentric Case-control Study of First-episode Psychosis (EU-GEI)

  • Sideli, Lucia
  • Schimmenti, Adriano
  • La Barbera, Daniele
  • La Cascia, Caterina
  • Ferraro, Laura
  • Aas, Monica
  • Alameda, Luis
  • Velthorst, Eva
  • Fisher, Helen L.
  • Caretti, Vincenzo
  • Trotta, Giulia
  • Tripoli, Giada
  • Quattrone, Diego
  • Gayer-Anderson, Charlotte
  • Seminerio, Fabio
  • Sartorio, Crocettarachele
  • Marrazzo, Giovanna
  • Lasalvia, Antonio
  • Tosato, Sarah
  • Tarricone, Ilaria
  • Berardi, Domenico
  • D'Andrea, Giuseppe
  • Arango, Celso
  • Arrojo, Manuel
  • Bernardo, Miguel
  • Bobes, Julio
  • Sanjuán, Julio
  • Santos, José Luis
  • Menezes, Paulo Rossi
  • Del-Ben, Cristina Marta
  • Jongsma, Hannah E.
  • Jones, Peter B.
  • Kirkbride, James B.
  • Llorca, Pierre-Michel
  • Tortelli, Andrea
  • Pignon, Baptiste
  • de Haan, Lieuwe
  • Selten, Jean-Paul
  • Van Os, Jim
  • Rutten, Bart P. F.
  • Di Forti, Marta
  • Morgan, Craig
  • Murray, Robin M.
[Background and hypothesis] Evidence suggests that childhood maltreatment (ie, childhood abuse and childhood neglect) affects educational attainment and cognition. However, the association between childhood maltreatment and Intelligence Quotient (IQ) seems stronger among controls compared to people with psychosis. We hypothesised that: the association between childhood maltreatment and poor cognition would be stronger among community controls than among people with first-episode of psychosis (FEP); compared to abuse, neglect would show stronger associations with educational attainment and cognition; the association between childhood maltreatment and IQ would be partially accounted for by other risk factors; and the association between childhood maltreatment, educational attainment, and IQ would be stronger among patients with affective psychoses compared to those with nonaffective psychoses., [Study Design] 829 patients with FEP and 1283 community controls from 16 EU-GEI sites were assessed for child maltreatment, education attainment, and IQ., [Study Results] In both the FEP and control group, childhood maltreatment was associated with lower educational attainment. The association between childhood maltreatment and lower IQ was robust to adjustment for confounders only among controls. Whereas childhood neglect was consistently associated with lower attainment and IQ in both groups, childhood abuse was associated with IQ only in controls. Among both patients with affective and nonaffective psychoses, negative associations between childhood maltreatment and educational attainment were observed, but the crude association with IQ was only evident in affective psychoses., [Conclusions] Our findings underscore the role of childhood maltreatment in shaping academic outcomes and cognition of people with FEP as well as controls., The EU-GEI Study is funded by grant agreement HEALTH-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework Programme, and Grant 2012/0417-0 from the São Paulo Research Foundation. B.P.F. Rutten is funded by a VIDI award (no. 91.718.336) from the Netherlands Scientific Organization. H. L. Fisher, C. Gayer-Anderson, and C. Morgan are supported by the Economic and Social Research Council (ESRC) Centre for Society and Mental Health at King’s College London [ES/S012567/1]. C. Arango has received support by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements, FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso and Fundación Alicia Koplowitz. J.B. Kirkbride is supported by the NIHR University College London Hospital Biomedical Research Centre., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Genetic variants associated with longitudinal changes in brain structure across the lifespan

  • Brouwer, Rachel M.
  • Tordesillas-Gutiérrez, Diana
  • Crespo-Facorro, Benedicto
  • Hulshoff Pol, Hilleke E.
et al., Human brain structure changes throughout the lifespan. Altered brain growth or rates of decline are implicated in a vast range of psychiatric, developmental and neurodegenerative diseases. In this study, we identified common genetic variants that affect rates of brain growth or atrophy in what is, to our knowledge, the first genome-wide association meta-analysis of changes in brain morphology across the lifespan. Longitudinal magnetic resonance imaging data from 15,640 individuals were used to compute rates of change for 15 brain structures. The most robustly identified genes GPR139, DACH1 and APOE are associated with metabolic processes. We demonstrate global genetic overlap with depression, schizophrenia, cognitive functioning, insomnia, height, body mass index and smoking. Gene set findings implicate both early brain development and neurodegenerative processes in the rates of brain changes. Identifying variants involved in structural brain changes may help to determine biological pathways underlying optimal and dysfunctional brain development and aging., The ENIGMA-Plasticity Working Group is part of the ENIGMA World Aging Center, funded by NIA grants R56 AG058854 and R01 AG058854. The ENIGMA Consortium core funding was supported by NIH Consortium Grant U54 EB020403, supported by a cross-NIH alliance that funds Big Data to Knowledge Centers of Excellence. 1000BRAINS: 1000BRAINS is a population-based cohort based on the Heinz-Nixdorf Recall Study and is supported, in part, by the German National Cohort. We thank the Heinz Nixdorf Foundation (Germany) for their generous support in terms of the Heinz Nixdorf Study. The authors are supported by the Initiative and Networking Fund of the Helmholtz Association (Svenja Caspers) and the European Union’s Horizon 2020 Research and Innovation Programme under grant agreements 785907 (Human Brain Project SGA2; Svenja Caspers, Sven Cichon and Katrin Amunts). This work was further supported by the German Federal Ministry of Education and Research (BMBF) through the Integrated Network IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental Disorders) under the auspices of the e:Med Program (grant 01ZX1314A; Sven Cichon) and by the Swiss National Science Foundation (SNSF, grant 156791; Sven Cichon). The authors acknowledge grants supporting their work from the European Union’s Horizon 2020 Research and Innovation Programme (H2020/2014–2020) under grant agreements 667302 (CoCA), 728018 (Eat2beNICE), 785907 (HBP SGA2) and 772376 (EScORIAL) and the Netherlands ALS Foundation.Additional support is received from the European Community’s Seventh Framework Programme (FP7/2007—2013) under grant agreements n° 602805 (Aggressotype), n° 603016 (MATRICS), n° 602450 (IMAGEMEND) and n° 278948 (TACTICS) and from the European Community’s Horizon 2020 Programme (H2020/2014—2020) under grant agreements n° 643051 (MiND) and n° 667302 (CoCA). FP7 Ideas: the European Research Council (ERC-230374 to D.B.). This work was supported by Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012 and PI19/024), co-financed by ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds; European Union Seventh Framework Program under grant agreements FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement 115916, Project PRISM and grant agreement 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña. The Horizon 2020 funded ERC Advanced Grant ‘STRATIFY’ (Brain network based stratification of reinforcement-related disorders) (695313). The FP7 project MATRICS (603016). The research leading to these results also received support from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement 278948 (TACTICS), 602805 (Aggressotype), 603016 (MATRICS) and 602450 (Imagemend) and the Innovation Medicine Initiative grants 115300 (EU-AIMS) and 777394 (AIMS-2-TRIALS).PAFIP: PAFIP was supported by the Instituto de Salud Carlos III (PI14/00639, PI14/00918 and PI17/01056) and Fundación Instituto de Investigación Marqués de Valdecilla (NCT0235832 and NCT025KG Jebsen Stiftelsen and H2020 CoMorMent (847776).34363). European Union Marie Curie Research Training Network (MRTN-CT-2006-035987)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Virtual ontogeny of cortical growth preceding mental illness

  • Patel, Yash
  • Shin, Jean
  • Abé, Christoph
  • Agartz, Ingrid
  • Alloza, Clara
  • Alnæs, Dag
  • Ambrogi, Sonia
  • Antonucci, Linda A.
  • Arango, Celso
  • Arolt, Volker
  • Auzias, Guillaume
  • Gruber, Oliver
  • Haavik, Jan
  • McDonald, Colm
  • Hahn, Tim
  • Harrison, Ben J.
  • Heindel, Walter
  • Henskens, Frans
  • Heslenfeld, Dirk J.
  • Hilland, Eva
  • King, Joseph A.
  • Vernooij, Meike W.
  • Hoekstra, Pieter J.
  • Hohmann, Sarah
  • Holz, Nathalie
  • Howells, Fleur M.
  • McIntosh, Andrew
  • Ipser, Jonathan C.
  • Meinert, Susanne
  • Hoogman, Martine
  • Kircher, Tilo
  • Kochunov, Peter
  • Vieta, Eduard
  • Koopowitz, Sheri-Michelle
  • Landén, Mikael
  • Landrø, Nils Inge
  • Lawrie, Stephen
  • Michie, Patricia T.
  • Ayesa Arriola, Rosa
  • Mitchell, Philip
  • Moreno-Alcázar, Ana
  • Franke, Barbara
  • Mowry, Bryan
  • Bau, Claiton H. D.
  • Muratori, Filippo
  • Nabulsi, Leila
  • Nenadić, Igor
  • O'Gorman Tuura, Ruth
  • Oosterlaan, Jaap
  • Overs, Bronwyn
  • Pantelis, Christos
  • Banaj, Nerisa
  • Parellada, Mara
  • van Rooij, Daan
  • Vilarroya, Oscar
  • Pariente, Jose C.
  • Pauli, Paul
  • Pergola, Giulio
  • Piarulli, Francesco Maria
  • Picon, Felipe
  • Piras, Fabrizio
  • Pomarol-Clotet, Edith
  • Pretus, Clara
  • Quidé, Yann
  • Banaschewski, Tobias
  • Weickert, Cynthia
  • Buitelaar, Jan
  • Radua, Joaquim
  • Ramos-Quiroga, J. Antoni
  • Rasser, Paul E.
  • Reif, Andreas
  • Retico, Alessandra
  • Roberts, Gloria
  • Rossell, Susan
  • Rovaris, Diego Luiz
  • Rubia, Katya
  • Weickert, Thomas
  • Sacchet, Matthew
  • Ching, Christopher R. K.
  • Bandeira, Cibele
  • Salavert, Josep
  • Salvador, Raymond
  • Sarró, Salvador
  • Sawa, Akira
  • Schall, Ulrich
  • Scott, Rodney
  • Selvaggi, Pierluigi
  • Westlye, Lars T.
  • Silk, Tim
  • Sim, Kang
  • Andreassen, Ole A.
  • Skoch, Antonin
  • Başgöze, Zeynep
  • Spalletta, Gianfranco
  • Spaniel, Filip
  • Stein, Dan J.
  • Steinsträter, Olaf
  • Stolicyn, Aleks
  • Whalley, Heather
  • Takayanagi, Yoichiro
  • Tamm, Leanne
  • Tavares, Maria
  • Pozzi, Elena
  • Teumer, Alexander
  • Thiel, Katharina
  • Cupertino, Renata Basso
  • Thomopoulos, Sophia I.
  • Tomecek, David
  • Tomyshev, Alexander S.
  • Willinger, David
  • Tordesillas-Gutiérrez, Diana
  • Tosetti, Michela
  • Uhlmann, Anne
  • Van Rheenen, Tamsyn
  • Veltman, Dick
  • Vázquez-Bourgon, Javier
  • Schmaal, Lianne
  • Jahanshad, Neda
  • Winter, Alexandra
  • Wittfeld, Katharina
  • Yang, Tony T.
  • Yoncheva, Yuliya
  • Bauer, Jochen
  • Zijlmans, Jendé L.
  • Baumeister, Sarah
  • Lebedeva, Irina
  • van Erp, Theo G. M.
  • Turner, Jessica
  • Jakobi, Babette
  • Castellanos, F. Xavier
  • Pausova, Zdenka
  • Thompson, Paul
  • Paus, Tomas
  • Bernardoni, Fabio
  • Bertolino, Alessandro
  • Bonnin, Caterina Del Mar
  • Brandeis, Daniel
  • Luna, Beatriz
  • Brem, Silvia
  • Jansen, Andreas
  • Bruggemann, Jason
  • Bülow, Robin
  • Bustillo, Juan R.
  • Calderoni, Sara
  • Calvo, Rosa
  • Canales-Rodríguez, Erick J.
  • Cannon, Dara M.
  • Carmona, Susanna
  • Carr, Vaughan J.
  • Lundervold, Astri J.
  • Janssen, Joost
  • Catts, Stanley V.
  • Chenji, Sneha
  • Chew, Qian Hui
  • Coghill, David
  • Connolly, Colm G.
  • Conzelmann, Annette
  • Craven, Alexander R.
  • Crespo-Facorro, Benedicto
  • Cullen, Kathryn
  • Dahl, Andreas
  • Jonassen, Rune
  • MacMaster, Frank P.
  • Dannlowski, Udo
  • Davey, Christopher G.
  • Deruelle, Christine
  • Díaz-Caneja, Covadonga M.
  • Dohm, Katharina
  • Ehrlich, Stefan
  • Epstein, Jeffery
  • Erwin-Grabner, Tracy
  • Eyler, Lisa T.
  • Kaiser, Anna
  • Fedor, Jennifer
  • Maglanoc, Luigi A.
  • Fitzgerald, Jacqueline
  • Foran, William
  • Ford, Judith M.
  • Fortea, Lydia
  • Fuentes-Claramonte, Paola
  • Fullerton, Janice
  • Furlong, Lisa
  • Gallagher, Louise
  • Kaleda, Vasiliy
  • Gao, Bingchen
  • Gao, Si
  • Mathalon, Daniel H.
  • Goikolea, Jose M.
  • Gotlib, Ian H.
  • Goya-Maldonado, Roberto
  • Grabe, Hans J.
  • Green, Melissa
  • Grevet, Eugenio H.
  • Groenewold, Nynke A.
  • Karantonis, James
  • Grotegerd, Dominik.
[Background]: Morphology of the human cerebral cortex differs across psychiatric disorders, with neurobiology and developmental origins mostly undetermined. Deviations in the tangential growth of the cerebral cortex during pre/perinatal periods may be reflected in individual variations in cortical surface area later in life., [Methods]: Interregional profiles of group differences in surface area between cases and controls were generated using T1-weighted magnetic resonance imaging from 27,359 individuals including those with attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depressive disorder, schizophrenia, and high general psychopathology (through the Child Behavior Checklist). Similarity of interregional profiles of group differences in surface area and prenatal cell-specific gene expression was assessed., [Results]: Across the 11 cortical regions, group differences in cortical area for attention-deficit/hyperactivity disorder, schizophrenia, and Child Behavior Checklist were dominant in multimodal association cortices. The same interregional profiles were also associated with interregional profiles of (prenatal) gene expression specific to proliferative cells, namely radial glia and intermediate progenitor cells (greater expression, larger difference), as well as differentiated cells, namely excitatory neurons and endothelial and mural cells (greater expression, smaller difference). Finally, these cell types were implicated in known pre/perinatal risk factors for psychosis. Genes coexpressed with radial glia were enriched with genes implicated in congenital abnormalities, birth weight, hypoxia, and starvation. Genes coexpressed with endothelial and mural genes were enriched with genes associated with maternal hypertension and preterm birth., [Conclusions]: Our findings support a neurodevelopmental model of vulnerability to mental illness whereby prenatal risk factors acting through cell-specific processes lead to deviations from typical brain development during pregnancy., This work was supported by the German Research Foundation (DFG Grant Nos. HA7070/2-2, HA7070/3, HA7070/4 [to TH]) and IZKF of the medical faculty of Münster (Grants No. Dan3/012/17 [to UD] and MzH 3/020/20 [to TH]), and NHMRC projects (Grant No. 1064643 [to BJH] and 1024570 [to CGD]). The CIAM study was supported by the University of Cape Town Research Committee, South African National Research Foundation, and the South African Medical Research Council (principal investigator [PI], Fleur M. Howells) and Grant No. R01MH117601 (to NJ). This work was funded by the German Research Foundation (Grant Nos. FOR2107 JA 1890/7-1 and FOR2107 JA 1890/7-2 [to AJ]) and Swinburne University scholarship/Australian Postgraduate Award (to JK). Collection of the COGSBD cohort was funded by the Jack Brockhoff Foundation, University of Melbourne, Barbara Dicker Brain Sciences Foundation, Rebecca L Cooper Foundation, and the Society of Mental Health Research (to JK). This work was funded by the German Research Foundation (Grant Nos. FOR2107 KI588/14-1 and FOR2107 KI588/14-2 [to TK]). The St. Göran study was supported by grants from the Swedish Research Council (Grant No. 2018-02653 [to ML]), the Swedish foundation for Strategic Research (Grant No. KF10-0039 [to ML]), the Swedish Brain foundation (Grant No. FO2020-0261 [to ML]), and the Swedish Government under the LUA/ALF agreement (Grant Nos. ALF 20170019 and ALFGBG-716801 [to ML]). This work was supported by RFBR (Grant No. 20-013-00748 [to IL, AST]) and funded by the Health Research Board (Grant No. HRA_POR/2011/100 [to CM]). The Australian Schizophrenia Research Bank (ASRB) was supported by the NHMRC (Enabling Grant No. 386500), the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation, and the Schizophrenia Research Institute. Chief investigators for ASRB were VC, US, RSc, AJ, BM, PTM, SVC, FH, and CPa. This work was supported by Deutsche Forschungsgemeinschaft (Grant Nos. DFG NE 2254/2-1, NE 2254/3-1, NE2254/4-1 [to IN]), the University Research Priority Program “Integrative Human Physiology” at the University of Zurich (to ROT), an NHMRC Senior Principal Research Fellowship (Grant No. 1105825 [to CPa]), an NHMRC L3 Investigator Grant (Grant No. 1196508 [to CPa]), and NHMRC Program Grant (Grant No. 1150083 [to CPa]). ASRB was supported by the NHMRC (Enabling Grant No. 386500), the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation and the Schizophrenia Research Institute. Chief investigators for ASRB were VC, US, RSc, AJ, BM, PTM, SVC, FH, and CPa. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant (Agreement No. 798181 [to GP]). ASRB was supported by the NHMRC (Enabling Grant, ID 386500), the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation and the Schizophrenia Research Institute. Chief investigators for ASRB were VC, US, RSc, AJ, BM, PTM, SVC, FH, and CPa. The Imaging Genetics in Psychosis study was funded by Project Grants from the NHMRC (Grant Nos. APP630471 and APP1081603 [to YQ]) and the Macquarie University’s Australian Research Council (ARC) Centre of Excellence in Cognition and its Disorders (Grant No. CE110001021 [to YQ]). This work was supported by the Spanish Ministry of Science, Innovation and Universities/Economy and Competitiveness/Instituto de Salud Carlos III (Grant Nos. PI11/01766 and CPII19/00009 [to JR]), co-financed by European Regional Development Fund funds from the European Commission (“A Way of Making Europe”). ASRB was supported by the NHMRC (Enabling Grant No. 386500), the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation, and the Schizophrenia Research Institute. Chief investigators for ASRB were VC, US, RSc, AJ, BM, PTM, SVC, FH, and CPa. SR was supported by an NHMRC Senior Fellowship (Grant No. GNT1154651). Collection of the COGSBD cohort was funded by the Jack Brockhoff Foundation, University of Melbourne, Barbara Dicker Brain Sciences Foundation, Rebecca L Cooper Foundation, and the Society of Mental Health Research (to SR). This work was supported by NIHR; MRC (to KR), NIH (Grant Nos. MH-094268, MH-105660, and MH-107730 [to ASS]). The Neuroimaging of the Children's Attention Project cohort was funded by NHMRC, Australia (Grant No. 1065895). Earlier funding for the cohort as also provided by NHMRC (Grant No. 1008522) and a grant from the Collier Foundation. The ACPU cohort was funded by NHMRC, Australia (Project Grant Nos. 384419 and 569533 [to TS]). This work was supported by research grants from the National Healthcare Group, Singapore (Grant Nos. SIG/05004, SIG/05028, and SIG /1103), and the Singapore Bioimaging Consortium (RP C009/2006 [to KS]), and the Ministry of Health, Czech Republic - conceptual development of research organization (“Institute for Clinical and Experimental Medicine - IKEM, IN 00023001” [to ASk]). This study was supported by the Italian Ministry of Health (Grant No. RC/17-18-19-20-21/A [to GS]) and Ministry of Health of the Czech Republic (Grant No. NU20-04-00393 [to FS]). The Drakenstein Child Health Study (DCHS) cohort is funded by the Bill and Melinda Gates Foundation (Grant No. OPP 1017641) and the South African Medical Research Council. This DCHS contribution was made possible in part by a grant from Carnegie Corporation of New York. The statements made and views expressed are solely the responsibility of the author (DJS). STRADL study was supported and funded by the Wellcome Trust Strategic Award “Stratifying Resilience and Depression Longitudinally” (Grant No. 104036/Z/14/Z), and the Medical Research Council Mental Health Pathfinder Award “Leveraging routinely collected and linked research data to study the causes and consequences of common mental disorders” (MRC, Grant No. MC_PC_17209). Scottish Bipolar Family Study (SBFS) was supported by National Health Service Research Scotland, through the Scottish Mental Health Research Network (www.smhrn.org.uk), who provided assistance with subject recruitment and assessments. SBFS was conducted at the Brain Research Imaging Centre (http://www.bric.ed.ac.uk), which is supported by SINAPSE (Scottish Imaging Network, a Platform for Scientific Excellence, http://www.sinapse.ac.uk). Processing of the datasets used the resources provided by the Edinburgh Compute and Data Facility (http://www.ecdf.ed.ac.uk/) (ASt). TVR was supported by an NHMRC Early Career Fellowship (Grant No. GNT1088785). Collection of the COGSBD cohort was funded by the Jack Brockhoff Foundation, University of Melbourne, Barbara Dicker Brain Sciences Foundation, Rebecca L Cooper Foundation, and the Society of Mental Health Research (to TVR). EV was supported by the Spanish Ministry of Science and Innovation (PI18/00805) integrated into the Plan Nacional de I+D+I and co-financed by the ISCIII-Subdirección General de Evaluación and the FEDER; the Instituto de Salud Carlos III; the CIBERSAM (Centro de Investigación Biomédica en Red de Salud Mental); by the CERCA Programme/Generalitat de Catalunya and the Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement (Grant No. 2017SGR1355). This study was also supported by the Departament de Salut de la Generalitat de Catalunya, Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020 (Grant No. SLT006/17/00345) and the European Union Horizon 2020 research and innovation program (EU.3.1.1. Understanding health, wellbeing and disease: Grant Nos. 754907 and EU.3.1.3 [to EB]; Treating and managing disease: Grant No. 945151 [to EV]). This study was supported by the National Center for Complementary and Integrative Health (Grant Nos. R21AT009173 and R61AT009864 [to TTY]); by the National Center for Advancing Translational Sciences (CTSI), National Institutes of Health, through UCSF-CTSI (Grant No. UL1TR001872 [to TTY]); by the American Foundation for Suicide Prevention (Grant No. SRG-1-141-18 [to TTY]); by UCSF Research Evaluation and Allocation Committee (REAC) and J. Jacobson Fund (to TTY); by the NIMH (Grant No. R01MH085734 [to TTY]); and by the Brain and Behavior Research Foundation (formerly NARSAD) (to TTY). This work was supported by a personal Veni grant to MH from the Netherlands Organization for Scientific Research (NWO, Grant No. 91619115 [to MH]) and European Community’s Horizon 2020 Programme (H2020/2014 – 2020) (Grant Agreements Nos. 667302 [CoCA], 728018 [Eat2beNICE], and 847879 [PRIME] [to BF]). JBu has been supported by the EU-AIMS (European Autism Interventions) and AIMS-2-TRIALS programmes, which receive support from Innovative Medicines Initiative Joint Undertaking Grant Nos. 115300 and 777394, the resources of which are composed of financial contributions from the European Union’s FP7 and Horizon 2020 Programmes, and from the European Federation of Pharmaceutical Industries and Associations companies’ in-kind contributions, and AUTISM SPEAKS, Autistica and SFARI; and by the Horizon 2020–supported programme CANDY (Grant No. 847818 [to JBu]). This work is supported by Grant No. NIA T32AG058507 and NIH Grant No. U54EB020403 from the Big Data to Knowledge (BD2K) Program (to CRKC). ENIGMA MDD work is supported by NIH (Grant Nos. U54 EB020403 [to PT], R01 MH116147 [to PT], and R01 MH117601 [to NJ and LS]). LS was supported by an NHMRC Career Development Fellowship (Grant No. 1140764). This work was supported by the National Center for Research Resources at the NIH (Grant Nos. NIH 1 U24 RR021992 [Function Biomedical Informatics Research Network], NIH 1 U24 RR025736-01 [Biomedical Informatics Research Network Coordinating Center; http://www.birncommunity.org]). TGMvE is supported by ENIGMA’s NIH BD2K initiative (Grant No. U54 EB020403), ENIGMA Sex Differences (Grant No. R01MH116147), and ENIGMA-COINSTAC: Advanced Worldwide Transdiagnostic Analysis of Valence System Brain Circuits (Grant No. R01MH121246). This work was supported by the NIH (Grant No. R01MH121246 [to JT, Calhoun, and TGMvE]). This work was supported in part by NIH (Grant No. U54 EB020403 [to PT])., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

In vivo white matter microstructure in adolescents with early-onset psychosis: a multi-site mega-analysis

  • Barth, Claudia
  • Crespo-Facorro, Benedicto
  • Tordesillas-Gutiérrez, Diana
et al., Emerging evidence suggests brain white matter alterations in adolescents with early-onset psychosis (EOP; age of onset <18 years). However, as neuroimaging methods vary and sample sizes are modest, results remain inconclusive. Using harmonized data processing protocols and a mega-analytic approach, we compared white matter microstructure in EOP and healthy controls using diffusion tensor imaging (DTI). Our sample included 321 adolescents with EOP (median age = 16.6 years, interquartile range (IQR) = 2.14, 46.4% females) and 265 adolescent healthy controls (median age = 16.2 years, IQR = 2.43, 57.7% females) pooled from nine sites. All sites extracted mean fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AD) for 25 white matter regions of interest per participant. ComBat harmonization was performed for all DTI measures to adjust for scanner differences. Multiple linear regression models were fitted to investigate case-control differences and associations with clinical variables in regional DTI measures. We found widespread lower FA in EOP compared to healthy controls, with the largest effect sizes in the superior longitudinal fasciculus (Cohen’s d = 0.37), posterior corona radiata (d = 0.32), and superior fronto‐occipital fasciculus (d = 0.31). We also found widespread higher RD and more localized higher MD and AD. We detected significant effects of diagnostic subgroup, sex, and duration of illness, but not medication status. Using the largest EOP DTI sample to date, our findings suggest a profile of widespread white matter microstructure alterations in adolescents with EOP, most prominently in male individuals with early-onset schizophrenia and individuals with a shorter duration of illness., ENIGMA Core: U.S. National Institutes of Health grants, R01 EB015611, U54 EB020403, R01 MH116147, R01 MH117601, R01 MH121246, S10 OD023696. YTOP: The Research Council of Norway (223273, 2137000, 250358, 288083); South-Eastern Norway Regional Health Authority (2017112, 2022080); KG Jebsen Stiftelsen (SKGJ-MED-008). MADRID: Celso Arango has received funding from CIBERSAM: Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, co-financed by ERDF Funds from the European Commission, “A way of making Europe”; CIBERSAM; Instituto de Investigación Sanitaria Gregorio Marañón; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2, Youth Employment Operational Program and Youth Employment Initiative); European Social Fund and EU Structural Funds; EU Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909, FP7-HEALTH-2009-2.2.1-3-242114, FP7-HEALTH-2013-2.2.1-2-602478, and FP7-HEALTH-2013-2.2.1-2-603196; EU H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña. Covadonga M. Díaz-Cenaj has received grant support from Instituto de Salud Carlos III (PI17/00481, PI20/00721, JR19/00024). FEMS: This project was supported by an unrestricted grant from AstraZeneca. Michael Berk is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (1059660 and APP1156072). SCAPS: The Swedish Research Council (521-2014-3487, 2017-00949); FORMAS (259-2012-31). OXFORD: MRC G0500092. PAFIP: This study was supported by grants from Carlos III Health Institute (IPI17/00402, PI17/01056, PI14/00639 and PI14/00918) cofunded by The European Union through FEDER funds and Fundación Instituto de Investigación Marqués de Valdecilla (NCT0235832 and NCT02534363). No pharmaceutical company has financially supported the study. BARCELONA: Inmaculada Baeza has received research funds from the Spanish Ministry of Health, Instituto de Salud Carlos II, supported by ERDF Funds from the European Comission (PI18/0242 and PI21/0391), “Otra manera de hacer Europa”, and Fundación Alcia Koplowitz. Elena de la Serna has received grant support from Instituto de Salud Carlos III (PI20/00654). Gisela Sugranyes has received research funds from Instituto de Salud Carlos III (PI1800976 and PI2100330), the Alicia Koplowitz Foundation (AKOPLOWITZ20_004), Ajut a la Recerca Pons Bartran (FCRB_PB1_2018) and a Brain and Behaviour Research Foundation NARSAD 2017 Young Investigator Grant (26731). UCLA: NIMH grants U01MH081902, P50MH066286., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium

  • Schijven, Dick
  • Postema, Merel C.
  • Fukunaga, Masaki
  • Tordesillas-Gutiérrez, Diana
  • Crespo-Facorro, Benedicto
  • Francks, Clyde
ENIGMA consortium: et al., Left-right asymmetry is an important organizing feature of the healthy brain that may be altered in schizophrenia, but most studies have used relatively small samples and heterogeneous approaches, resulting in equivocal findings. We carried out the largest case-control study of structural brain asymmetries in schizophrenia, with MRI data from 5,080 affected individuals and 6,015 controls across 46 datasets, using a single image analysis protocol. Asymmetry indexes were calculated for global and regional cortical thickness, surface area, and subcortical volume measures. Differences of asymmetry were calculated between affected individuals and controls per dataset, and effect sizes were meta-analyzed across datasets. Small average case-control differences were observed for thickness asymmetries of the rostral anterior cingulate and the middle temporal gyrus, both driven by thinner left-hemispheric cortices in schizophrenia. Analyses of these asymmetries with respect to the use of antipsychotic medication and other clinical variables did not show any significant associations. Assessment of age- and sex-specific effects revealed a stronger average leftward asymmetry of pallidum volume between older cases and controls. Case-control differences in a multivariate context were assessed in a subset of the data (N = 2,029), which revealed that 7% of the variance across all structural asymmetries was explained by case-control status. Subtle case-control differences of brain macrostructural asymmetry may reflect differences at the molecular, cytoarchitectonic, or circuit levels that have functional relevance for the disorder. Reduced left middle temporal cortical thickness is consistent with altered left-hemisphere language network organization in schizophrenia., The ENIGMA project is in part supported by the National Institute of Biomedical Imaging and Bioengineering of the NIH (U54EB020403). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Individual Funding Sources: D.S., M.C.P., S.E.F., and C.F.: Max Planck Society (Germany). R.A.-A.: Miguel Servet contract from the Carlos III Health Institute (CP18/00003). J.V.-B.: Instituto de Investigación Sanitaria Valdecilla (IDIVAL) (INT/A21/10, INT/A20/04). D.A.: South-Eastern Norway Regional Health Authority (2019107, 2020086). L.T.W.: Research Council of Norway (223273, 300767), South-Eastern Norway Regional Health Authority (2019101), and European Research Council under the European Union’s Horizon 2020 Research and Innovation Program (ERC StG, 802998). O.A.A.: Research Council of Norway (223273, 275054), KG Jebsen Stiftelsen, South East Norway Health Authority (2017-112, 2019-108). P.K.: NIH (R01MH123163, R01EB015611). M.J.G.: National Health and Medical Research Council (NHMRC) (630471, 1051672, 1081603). C.P.: NHMRC Senior Principal Research Fellowship (1105825), NHMRC L3 Investigator Grant (1196508). V.D.C.: NIH (R01MH118695), NSF (2112455). J.M.F.: Senior Research Career Scientist Award, Department of Veterans Affairs. P.F.-C.: Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Instituto de Salud Carlos III, cofunded by European Union (European Regional Development Fund (ERDF)/European Social Fund (ESF), “Investing in your future”): Sara Borrell Research contract (CD19/00149). G.S.: Italian Ministry of Health (RC17-18-19-20-21/A). A.N.V.: National Institute of Mental Health (NIMH), Canadian Institutes of Health Research (CIHR), Canada Foundation for Innovation, Centre for Addiction and Mental Health (CAMH) Foundation, University of Toronto. Y.-C.C.: Korean Mental Health Technology R&D Project (HL19C0015) and Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI18C2383), funded by the Ministry of Health & Welfare, Republic of Korea. J.M.S.: NIH (1P20RR021938-01). A.R.M.: NIH (P30GM122734, R01MH101512). C.M.D.-C.: Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (PI17/00481, PI20/00721, JR19/00024). S. Cervenka: Swedish Research Council (523-2014-3467). M. Kirschner: Swiss National Science Foundation (SNSF) (P2SKP3_178175). T.H.: CIHR (142255), Ministry of Health of the Czech Republic (16-32791A, NU20-04-00393), Brain & Behavior Research Foundation (BBRF) Young and Independent Investigator Awards. A. James: Medical Research Council (MRC) (G0500092). P.H.: NARSAD grant from the BBRF (28445), Research Grant from the Novartis Foundation (20A058). R.C.G.: NIH (1R01MH117014, 1R01MH119219). N.J.: NIH (R01MH117601). S.E.M.: NHMRC (APP1172917). J.A.T.: NIH (R01MH1​21246). Dataset-Specific Funding Sources and Acknowledgments: AMC: Supported by grants from The Netherlands Organisation for Health Research and Development (ZonMw) (3160007, 91676084, 31160003, 31180002, 31000056, 2812412, 100001002, 100002034), the Dutch Research Council (NWO) (90461193, 40007080, 48004004, 40003330), the Amsterdam Brain Imaging Platform, Neuroscience Campus Amsterdam, and the Dutch Brain Foundation. Processing with FreeSurfer was performed on the Dutch e-Science Grid through BiG Grid project and COMMIT project “e-Biobanking with imaging for healthcare,” which are funded by the NWO. ASRB: Australian Schizophrenia Research Bank, supported by the NHMRC (Enabling Grant, 386500), the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation, and the Schizophrenia Research Institute. Chief Investigators for ASRB were S.V.C., P.T.M., B.J.M., U.S., R.J.S., V.J.C., F.A.H., C.P., Assen Jablensky. We thank C.M.L., the ASRB Manager, and acknowledge the help of Jason Bridge for ASRB database queries. CAMH: Datasets were collected and shared with support from the CAMH Foundation and the CIHR. CASSI (Cognitive and Affective Symptoms in Schizophrenia Intervention): Supported by the University of New South Wales School of Psychiatry, the NHMRC (568807), Neuroscience Research Australia, the Schizophrenia Research Institute utilizing infrastructure funding from NSW Ministry of Health, the Macquarie Group Foundation, and the ASRB (see above). CIAM (Cortical Inhibition and Attentional Modulation): The CIAM group (PI: F.M.H.) was supported by the University Research Committee, University of Cape Town; South African National Research Foundation (NRF); South African Medical Research Council (SA MRC). CLING (Clinical Neuroscience Goettingen): Sample data collection partially supported by the Deutsche Forschungsgemeinschaft (DFG) (GR1950/5-1 to O.G.). COBRE (Center for Biomedical Research Excellence): Supported by NIH (R01EB006841, P20GM103472, 5R01MH094524 to V.D.C. and J.A.T. R01AA021771 and P50AA022534 to J.M.S.), and the NSF (1539067). EdinburghEHRS: Funded by the MRC (G9226254, G9825423), the Dr. Mortimer and Theresa Sackler Foundation. EdinburghFunc: Funded by the MRC Clinical Training Fellowship (G84/5699) and Health Foundation Clinician Scientist Fellowship (2268/4295). EdinburghSFMH: Funded by an award from the Translational Medicine Research Collaboration (NS_EU_166), Scottish Enterprise, Pfizer, the Dr. Mortimer and Theresa Sackler Foundation. The University of Edinburgh is a charitable body, registered in Scotland, with registration number SC005336. Is e buidheann carthannais a th’ ann an Oilthigh Dhùn Èideann, clàraichte an Alba, àireamh clàraidh SC005336. EONCKS: Supported by the SA MRC and the New Partnership for Africa’s Development initiative through the Department of Science and Technology of South Africa (#65174). ESO: Supported by the Ministry of Health of the Czech Republic (NU20-04-00393). FBIRN (Function Biomedical Informatics Research Network): Supported by the National Center for Research Resources at the NIH (1 U24 RR021992 (FBIRN) and 1 U24 RR025736-01 (Biomedical Informatics Research Network Coordinating Center; http://www.birncommunity.org)). Data were processed by the UCI High-Performance Computing cluster supported by Joseph Farran (supported by NIMH R01 MH-58262), Harry Mangalam, and Adam Brenner (supported by NIH 5R01 MH61603, 2R01MH058251), and the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH (through grant UL1 TR000153). FBIRN thank Mrs. Liv McMillan for overall study coordination. FOR2107 Marburg: Funded by the DFG, T.T.J.K. (speaker FOR2107; KI588/14-1, KI588/14-2), Axel Krug (KR3822/5-1, KR3822/7-2), I.N. (NE2254/1-2, NE2254/3-1, NE2254/4-1), Carsten Konrad (KO4291/3-1), and A. Jansen (JA1890/7-1, JA1890/7-2). FOR2107 Münster: Funded by the DFG (FOR2107 DA1151/5-1, DA1151/5-2 to U.D.; SFB-TRR58, Projects C09 and Z02 to U.D.) and the Interdisciplinary Center for Clinical Research of the medical faculty of Münster (Dan3/012/17 to U.D.). Frankfurt: MRI was performed at the Frankfurt Brain Imaging Centre, supported by the DFG and the German Ministry for Education and Research (Brain Imaging Center Frankfurt/Main, DLR01GO0203). GAP (Genetics and Psychosis): The GAP dataset represents independent research funded by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre at South London, Maudsley National Health Service (NHS) Foundation Trust, and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. GIPSI: Supported by “PRISMA U.T” Colciencias Invitación 990 del 3 de Agosto de 2017, Código 111577757629, Contrato 781 de 2017. GROUP: We thank Truda Driesen and Inge Crolla for their coordinating roles in the data collection, as well as the G.R.O.U.P. investigators: R.S.K., Don H. Linszen, Jim van Os, Durk Wiersma, Richard Bruggeman, W.C., L.dH., Lydia Krabbendam, Inez Myin-Germeys. Infrastructure for the GROUP study is funded through the Geestkracht programme of ZonMw (10-000-1001), and matching funds from participating pharmaceutical companies (Lundbeck, AstraZeneca, Eli Lilly, Janssen Cilag) and universities and mental health care organizations (Amsterdam: Academic Psychiatric Centre of the Academic Medical Center and the mental health institutions: GGZ Ingeest, Arkin, Dijk en Duin, GGZ Rivierduinen, Erasmus Medical Centre, GGZ Noord Holland Noord; Groningen: University Medical Center Groningen and the mental health institutions: Lentis, GGZ Friesland, GGZ Drenthe, Dimence, Mediant, GGNet Warnsveld, Yulius Dordrecht and Parnassia psycho-medical center, The Hague; Maastricht: Maastricht University Medical Centre and the mental health institutions: GGzE, GGZ Breburg, GGZ Oost-Brabant, Vincent van Gogh voor Geestelijke Gezondheid, Mondriaan, Virenze riagg, Zuyderland GGZ, MET ggz, Universitair Centrum Sint-Jozef Kortenberg, CAPRI University of Antwerp, PC Ziekeren Sint-Truiden, PZ Sancta Maria Sint-Truiden, GGZ Overpelt, OPZ Rekem; Utrecht: University Medical Center Utrecht and the mental health institutions Altrecht, GGZ Centraal, and Delta). HMS (Homburg Multidiagnosis Study): Sample data collection was supported by a grant of the Competence Network Schizophrenia to O.G. HUBIN (Human Brain Informatics): Supported by the Swedish Research Council (K2015-62X-15077-12-3), 2017-00949, the regional agreement on medical training and clinical research between Stockholm County Council and the Karolinska Institutet, the Knut and Alice Wallenberg Foundation. Huilong: Funded by the National Natural Science Foundation of China (81761128021; 31671145; 81401115; 81401133), Beijing Municipal Science & Technology Commission grant (Z141107002514016), Beijing Natural Science Foundation (7162087), Beijing Municipal Administration of Hospitals Clinical medicine Development of special funding (XMLX201609; zylx201409). IGP: Imaging Genetics in Psychosis study, funded by Project Grants from the NHMRC (APP630471 and APP1081603), and the Macquarie University’s ARC Centre of Excellence in Cognition and its Disorders (CE110001021). This project used participants from the ASRB (see above), using an infrastructure grant from the NSW Ministry of Health. IMH: Supported by research grants from the National Healthcare Group, Singapore (SIG/05004; SIG/05028), and the Singapore Bioimaging Consortium (RP C009/2006) awarded to K.S. KaSP: Supported by the Swedish Research Council (K2015-62X-15077-12-3), and by grants from the Swedish Medical Research Council (2009-7053, 2013-2838, 523-2014-3467), the Swedish Brain Foundation, Åhlén-siftelsen, Svenska Läkaresällskapet, Petrus och Augusta Hedlunds Stiftelse, Torsten Söderbergs Stiftelse, the AstraZeneca-Karolinska Institutet Joint Research Program in Translational Science, Söderbergs Königska Stiftelse, Professor Bror Gadelius Minne, Knut och Alice Wallenbergs stiftelse, the Swedish Federal Government under the LUA/ALF agreement (C.M.S., S. Cervenka), Centre for Psychiatry Research, KID-funding from the Karolinska Institutet. Madrid: Supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), cofinanced by ERDF Funds from the European Commission, “A way of making Europe,” CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program (FP7-4-HEALTH-2009-2.2.1-2-241909—Project EU-GEI, FP7-HEALTH-2013-2.2.1-2-603196—Project PSYSCAN, and FP7-HEALTH-2013-2.2.1-2-602478—Project METSY), European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (115916—Project PRISM, and 777394—Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz. MCIC: Supported by the NIH (NIH/NCRR P41RR14075, R01EB005846 to V.D.C.), the Department of Energy (DE-FG02- 99ER62764), the Mind Research Network, the Morphometry BIRN (1U24, RR021382A), the Function BIRN (U24RR021992-01, NIH.NCRR MO1 RR025758-01, NIMH 1RC1MH089257 to V.D.C.), the DFG (research fellowship to S.E.), and a NARSAD Young Investigator Award (to S.E.). MPRC: Support received from NIH (U01MH108148, 2R01EB015611, R01MH112180, R01DA027680, R01MH085646, P50MH103222, and T32MH067533), a State of Maryland contract (M00B6400091), and NSF grant (1620457). OLIN: Supported by NIH (R01MH106324, R01MH077945). Osaka: Partially supported by AMED (JP21dm0307002, JP21dm0207069, JP21dk0307103, JP21uk1024002, and JP21wm0425012), JSPS KAKENHI (JP20H03611, JP20K06920), and Intramural Research Grant (3-1) for Neurological and Psychiatric Disorders of NCNP. Computations were performed using Research Center for Computational Science, Okazaki, Japan. Oxford: We would like to thank the participants and their families, referring psychiatrists, and the Donnington Health Centre, Oxford. This study is supported by the MRC, OHSRC, UK EPSRC, BBSRC, and Wellcome Trust. PAFIP: We wish to thank all PAFIP research teams and all patients and family members who participated in the study. PAFIP has been funded by Instituto de Salud Carlos III through the projects PI14/00639, PI14/00918, and PI17/01056 (cofunded by ERDF/ESF “Investing in your future”), Health Research Institute Marques de Valdecilla (NTC0235832, NCT02534363), Instituto de Salud Carlos III, FIS 00/3095, 01/3129, PI020499, PI060507, PI10/00183, the SENY Fundació Research Grant (CI 2005‐0308007), the Fundación Marqués de Valdecilla (API07/011), MINECOSAF2013-46292-R, PSYSCAN (Exp.: HEALTH.2013.2.2.1-2_Grant agreement no. 603196). We want to particularly acknowledge the patients and the BioBankValdecilla (PT13/0010/0024) integrated in the Spanish National Biobanks Network for its collaboration. We thank IDIVAL Neuroimaging Unit for its help in the technical execution of this work. RSCZ: Supported in part by the RFBR (20-013-00748). SCORE: This study was supported in part by the SNSF (3232BO_119382). We thank the FePsy (Frueherkennung von Psychosen; early detection of psychosis) Study Group from the University of Basel, Department of Psychiatry, Switzerland, for the recruitment of the study participants. The FePsy Study was supported in part by grant no. SNF 3200-057216/1, ext./2, ext./3. SNUH: Supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) and the Korea Brain Research Institute (KBRI) basic research program through the KBRI, funded by the Ministry of Science, ICT & Future Planning (2019R1C1C1002457, 2020M3E5D9079910, 21-BR-03–01). SWIFT: Supported in part by the SNSF (320030_146789). TOP: Supported by the Research Council of Norway (#160181, 190311, 223273, 213837, 249711), the South-East Norway Health Authority (2014114, 2014097, 2017- 112), the Kristian Gerhard Jebsen Stiftelsen (SKGJ‐MED‐008), and the European Community’s Seventh Framework Programme (FP7/2007–2013), grant agreement no. 602450 (IMAGEMEND). UCISZ: Supported by the NIMH (R21MH097196 to T.G.M.v.E.). Data were processed by the UCI High-Performance Computing cluster (see FBIRN). UMCU: Supported by ZonMw (90802123, 91746370 to H.E.H.P., and 10-000-1001 to R.S.K.). UNIBA: Supported by grant funding from the Italian Ministry of Research (2017M7SZM8_004, PI A.B.; 2017K2NEF4, PI G.P.). UNIMAAS: Supported by ZonMw (91112002) and by a personal grant to T.v.A. (ZonMw-VIDI: 91712394). This clinical trial was registered in the Dutch clinical trial registry under ID: NTR5094 (https://trialsearch.who.int/Trial2.aspx?TrialID=NTR5094). Zurich: Funded by the SNSF., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mapping gray and white matter volume abnormalities in early-onset psychosis: an ENIGMA multicenter voxel-based morphometry study

  • Si, Shuqing
  • Tordesillas-Gutiérrez, Diana
S. Si et al., [Introduction] Regional gray matter (GM) alterations have been reported in early-onset psychosis (EOP, onset before age 18), but previous studies have yielded conflicting results, likely due to small sample sizes and the different brain regions examined. In this study, we conducted a whole brain voxel-based morphometry (VBM) analysis in a large sample of individuals with EOP, using the newly developed ENIGMA-VBM tool., [Methods] 15 independent cohorts from the ENIGMA-EOP working group participated in the study. The overall sample comprised T1-weighted MRI data from 482 individuals with EOP and 469 healthy controls. Each site performed the VBM analysis locally using the standardized ENIGMA-VBM tool. Statistical parametric T-maps were generated from each cohort and meta-analyzed to reveal voxel-wise differences between EOP and healthy controls as well as the individual-based association between GM volume and age of onset, chlorpromazine (CPZ) equivalent dose, and other clinical variables., [Results] Compared with healthy controls, individuals with EOP showed widespread lower GM volume encompassing most of the cortex, with the most marked effect in the left median cingulate (Hedges’ g = 0.55, p = 0.001 corrected), as well as small clusters of lower white matter (WM), whereas no regional GM or WM volumes were higher in EOP. Lower GM volume in the cerebellum, thalamus and left inferior parietal gyrus was associated with older age of onset. Deficits in GM in the left inferior frontal gyrus, right insula, right precentral gyrus and right superior frontal gyrus were also associated with higher CPZ equivalent doses., [Conclusion] EOP is associated with widespread reductions in cortical GM volume, while WM is affected to a smaller extent. GM volume alterations are associated with age of onset and CPZ equivalent dose but these effects are small compared to case-control differences. Mapping anatomical abnormalities in EOP may lead to a better understanding of the role of psychosis in brain development during childhood and adolescence., MB is supported by a NHMRC Senior Principal Research Fellowship and Leadership 3 Investigator grant (1156072 and 2017131). The Hospital Clinic Barcelona - IDIBAPS cohort has been supported by the following funding agencies: the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, (PI18/00976, PI20/00654, PI02100330), Ajut a la Recerca Pons Bartran, the Alicia Koplowitz Foundation, Brain and Behavior Research Foundation (NARSAD Young Investigator Award 2017) and Strategic Research and Innovation Plan in Health (PERIS), Department of Health, Government of Catalonia. CA, CDC and JJ are supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, financed by the European Union - NextGenerationEU (PMP21/00051), PI19/01024, PI20/00721, JR19/00024. CIBERSAM, Madrid Regional Government (S2022/BMD-7216 (AGES 3-CM)), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz. YTOP cohort is supported by The Research Council of Norway (223273, 213700, 250358, 288083, 334326); South-Eastern Norway Regional Health Authority (2017112); KG Jebsen Stiftelsen (SKGJ-MED-008). SCAPS cohort is supported by The Swedish Research Council (521-2014-3487, 2017-00949); FORMAS (259-2012-31). RUND cohort is supported by South-Eastern Norway Regional Health Authority (#2004-259, # 2006-186). MPP is supported by the grant RYC2021‐031228‐I funded by MCIN/AEI/10.13039/50110 0011033 and by the “European Union NextGenerationEU/ PRTR”. PM’s work has been partially funded by National funds, through the Foundation for Science and Technology (FCT) - project UIDB/50026/2020 and UIDP/50026/2020 and by the project NORTE-01-0145-FEDER-000039, supported by Norte Portugal Regional Operational Program (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). The study was partially funded by the Italian Ministry of Health, Ricerca Corrente 23. SIT, NJ, PMT were supported in part by NIH grants: R01AG059874, R01MH134004, R01MH116147, R01MH121246, and P41EB015922. JJC is supported by a National Health and Medical Research Council (NHMRC) Emerging Leadership EL1 Fellowship (2008197). IBH is supported by a National Health and Medical Research Council (NHMRC) Leadership 3 Fellowship (2016346)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Accelerated Cortical Thinning in Schizophrenia Is Associated With Rare and Common Predisposing Variation to Schizophrenia and Neurodevelopmental Disorders

  • González-Peñas, Javier
  • Alloza, Clara
  • Brouwer, Rachel
  • Díaz-Caneja, Covadonga M.
  • Costas, Javier
  • González-Lois, Noemí
  • Gallego, Ana Guil
  • Hoyos, Lucía de
  • Gurriarán, Xaquín
  • Andreu-Bernabeu, Álvaro
  • Romero-García, Rafael
  • Fañanás, Lourdes
  • Bobes, Julio
  • González-Pinto, Ana
  • Crespo-Facorro, Benedicto
  • Martorell, Lourdes
  • Arrojo, Manuel
  • Vilella, Elisabet
  • Gutiérrez-Zotes, Alfonso
  • Perez-Rando, Marta
  • Moltó, María Dolores
  • Buimer, Elizabeth
  • van Haren, Neeltje
  • Cahn, Wiepke
  • O'Donovan, Michael
  • Kahn, René S
  • Arango, Celso
  • Pol, Hilleke Hulshoff
  • Janssen, Joost
  • Schnack, Hugo
Schizophrenia is a highly heritable disorder characterized by increased cortical thinning throughout the life span. Studies have reported a shared genetic basis between schizophrenia and cortical thickness. However, no genes whose expression is related to abnormal cortical thinning in schizophrenia have been identified., This work was supported by Spanish Ministry of Science, Innovation and Universities Instituto de Salud Carlos III (Grant Nos. SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, and PI20/00721), cofinanced by European Regional Development Funds from the European Commission, “A way of making Europe,” CIBERSAM (Centro de Investigación Biomédica en Red de Salud Menta); Madrid Regional Government (Grant No. B2017/BMD-3740 AGES-CM-2), European Union Structural Funds; the European Union Seventh Framework Program (Grant Nos. FP7-4-HEALTH-2009-2.2.1-2-241909 [Project EU-GEI], FP7- HEALTH-2013-2.2.1-2-603196 [Project PSYSCAN], and FP7-HEALTH-2013-2.2.1-2-602478 [Project METSY]); and the European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (Grant No. 115916, Project PRISM, and Grant No. 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz, and Fundación Mutua Madrileña. CMD-C holds a Juan Rodés Grant from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (Grant No. JR19/00024). JG-P held a Sara Borrell grant during the development of the research from Instituto de Salud Carlos III (Grant No. CD20/00118)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs

  • Sønderby, Ida E.
  • Ching, Christopher R. K.
  • Thomopoulos, Sophia I.
  • Meer, Dennis van der
  • Sun, Daqiang
  • Villalón-Reina, Julio E.
  • Agartz, Ingrid
  • Amunts, Katrin
  • Arango, Celso
  • Armstrong, Nicola J.
  • Ayesa-Arriola, Rosa
  • Bakker, Geor
  • Bassett, Anne S.
  • Boomsma, Dorret I.
  • Bülow, Robin
  • Butcher, Nancy J.
  • Calhoun, Vince D.
  • Caspers, Svenja
  • Chow, Eva W C
  • Cichon, Sven
  • Ciufolini, Simone
  • Craig, Michael C.
  • Crespo-Facorro, Benedicto
  • Cunningham, Adam C.
  • Dale, Anders M.
  • Dazzan, Paola
  • de Zubicaray, Greig I.
  • Djurovic, Srdjan
  • Doherty, Joanne L.
  • Donohoe, Gary
  • Draganski, Bogdan
  • Durdle, Courtney A.
  • Ehrlich, Stefan
  • Emanuel, Beverly S.
  • Espeseth, Thomas
  • Fisher, Simon E.
  • Ge, Tian
  • Glahn, David C.
  • Grabe, Hans J.
  • Gur, Raquel E.
  • Gutman, Boris A.
  • Haavik, Jan
  • Håberg, Asta K.
  • Hansen, Laura A.
  • Hashimoto, Ryota
  • Hibar, Derrek P.
  • Holmes, Avram J.
  • Hottenga, Jouke-Jan
  • Hulshoff Pol, Hilleke E
  • Jalbrzikowski, Maria
  • Knowles, Emma E. M.
  • Kushan, Leila
  • Linden, David E J.
  • Liu, Jingyu
  • Lundervold, Astri J.
  • Martin-Brevet, Sandra
  • Martínez, Kenia
  • Mather, Karen A.
  • Mathias, Samuel R.
  • McDonald-McGinn, Donna M.
  • McRae, Allan F.
  • Medland, Sarah E.
  • Moberget, Torgeir
  • Modenato, Claudia
  • Monereo Sánchez, Jennifer
  • Moreau, Clara A.
  • Mühleisen, Thomas W.
  • Paus, Tomas
  • Pausova, Zdenka
  • Prieto, Carlos
  • Ragothaman, Anjanibhargavi
  • Reinbold, Céline S.
  • Reis Marques, Tiago
  • Repetto, Gabriela M.
  • Reymond, Alexandre
  • Roalf, David R.
  • Rodriguez-Herreros, Borja
  • Rucker, James J.
  • Sachdev, Perminder S.
  • Schmitt, James E.
  • Schofield, Peter R.
  • Silva, Ana I.
  • Stefansson, Hreinn
  • Stein, Dan J.
  • Tamnes, Christian K.
  • Tordesillas-Gutiérrez, Diana
  • Ulfarsson, Magnus O.
  • Vajdi, Ariana
  • van 't Ent, Dennis
  • Bree, Marianne B. M. van den
  • Vassos, Evangelos
  • Vázquez-Bourgon, Javier
  • Vila-Rodriguez, Fidel
  • Walters, G Bragi
  • Wen, Wei
  • Westlye, Lars T.
  • Wittfeld, Katharina
  • Zackai, Elaine H.
  • Stefánsson, Kári
  • Jacquemont, Sebastien
  • Thompson, Paul M.
  • Bearden, Carrie E.
  • Andreassen, Ole A.
  • ENIGMA-CNV Working Group
  • ENIGMA 22q11.2 Deletion Syndrome Additional
Data sharing is not applicable to this article as no new data were created or analyzed in this study., ENIGMA-CNV Additional Members: Manon Bernard, Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada. Nicholas B. Blackburn, Department of Human Genetics, School of Medicine, University of Texas Rio Grande Valley, Brownsville, Texas, USA; South Texas Diabetes and Obesity Institute, School of Medicine, University of Texas Rio Grande Valley, Brownsville, Texas, USA. Rune Bøen, Department of Medical Genetics, Oslo University Hospital, Oslo, Norway; Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital and University of Oslo, Oslo, Norway. Eco de Geus, Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; Amsterdam Public Health (APH) Research Institute, Amsterdam UMC, Amsterdam, The Netherlands. Sonja M. C. de Zwarte, Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. Marta Di Forti, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. Oleksandr Frei, Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health; Addiction, Oslo University Hospital and University of Oslo, Oslo, Norway and Center for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway, Vincent Frouin, Université Paris-Saclay, CEA, Neurospin, Gif-sur-Yvette, France. Masaki Fukunaga, Division of Cerebral Integration, National Institute for Physiological Sciences, Okazaki, Japan. Jayne Y. Hehir-Kwa, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Manon H. J. Hillegers, Department of Child and Adolescent Psychiatry/Psychology, Erasmus Medical Center, Rotterdam, The Netherlands. Per Hoffmann, Institute of Human Genetics, University of Bonn, Bonn, Germany; Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, Switzerland. Georg Homuth, Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany. Neda Jahanshad, Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA, USA. Sanne Koops, Department of Biomedical Sciences of Cells & Systems, Cognitive Neurosciences, University of Groningen, University Medical Center Groningen (UMCG), Groningen, The Netherlands. Kuldeep Kumar, Sainte Justine Research Center, University of Montreal, Montreal, QC, Canada. Masataka Kikuchi, Graduate School of Medicine, Osaka University, Osaka, Japan. Stephanie Le Hellard, NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway; Dr. Einar Martens Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway. Costin Leu, Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK; Stanley Center for Psychiatric Research, Broad Institute of Harvard and M.I.T, Cambridge, MA, USA. Robin M Murray, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. Terje Nærland, KG Jebsen Centre for Neurodevelopmental Disorders, University of Oslo, Oslo, Norway; NevSom, Department of Rare Disorders, Oslo University Hospital, Oslo, Norway. Lars Nyberg, Integrative Medical Biology (IMB) Umeå University, Umeå, Sweden; Department of Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands. Roel A. Ophoff, Center for Neurobehavioral Genetics, University of California Los Angeles, Los Angeles, CA, USA; Department of Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands. G Bruce Pike, Radiology and Clinical Neurosciences, University of Calgary, Calgary, AB, Canada. Sigrid B. Sando, Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; Department of Neurology and Clinical Neurophysiology, University Hospital of Trondheim, Trondheim, Norway. Jean Shin, The Hospital for Sick Children, Toronto, ON, Canada; Departments of Physiology and Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada. Elena Shumskaya, Donders Institute for Brain, Cognition, and Behavior, Nijmegen, The Netherlands. Sanjay M. Sisodiya, Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK; Chalfont Centre for Epilepsy, Chalfont-St-Peter, Bucks, UK. Vidar M. Steen, NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway; Dr. Einar Martens Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway. Alexander Teumer, Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany, Anne Uhlmann, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa. Margaret J. Wright, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia, ENIGMA 22q11.2 Deletion Syndrome Additional Members: Kevin M. Antshel, Department of Psychology, Syracuse University, Syracuse, NY, USA. Linda E. Campbell, University of Newcastle, Newcastle, NSW, Australia. Nicolas A. Crossley, Department of Psychiatry, Pontificia Universidad Católica de Chile, Santiago, Chile. T. Blaine Crowley, Division of Human Genetics and 22q and You Center, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Eileen Daly, Department of Forensic and Neurodevelopmental Sciences, and the Sackler Institute for Translational Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK. Ania M. Fiksinski, Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, ON, Canada; Dalglish Family 22q Clinic for Adults with 22q11.2 Deletion Syndrome, Toronto General Hospital, University Health Network, Toronto, ON, Canada; Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. Jennifer K. Forsyth, Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, CA, USA. Wanda Fremont, Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, NY, USA. Naomi J. Goodrich-Hunsaker, MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis, Davis, CA, USA; Department of Neurology, University of Utah, Salt Lake City, UT, USA. Maria Gudbrandsen, Department of Forensic and Neurodevelopmental Sciences, and the Sackler Institute for Translational Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK. Rachel K. Jonas, Semel Institute for Neuroscience and Human Behavior, Departments of Psychiatry and Biobehavioral Sciences and Psychology, University of California Los Angeles, Los Angeles, CA, USA. Wendy R. Kates, Department of Psychiatry and Behavioral Sciences, State University of New York at Upstate Medical University, Syracuse, NY, USA. Amy Lin, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, USA. Kathryn L. McCabe, Department of Psychiatry and Behavioral Sciences, State University of New York at Upstate Medical University, Syracuse, NY, USA; Department of Psychology, University of Newcastle, Newcastle, NSW, Australia. Hayley Moss, MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK. Declan G. Murphy, Department of Forensic and Neurodevelopmental Sciences, and the Sackler Institute for Translational Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK; Behavioural Genetics Clinic, Adult Autism Service, Behavioural and Developmental Psychiatry Clinical Academic Group, South London and Maudsley NHS Foundation Trust, London, UK. Kieran C. Murphy, Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland. Michael J. Owen, MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK. Kosha Ruparel, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. Tony. J. Simon, MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis, Davis, CA, USA. Therese van Amelsvoort, Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands. Jacob A. S. Vorstman, Department of Psychiatry, The Hospital for Sick Children, Toronto, ON, Canada., The Enhancing NeuroImaging Genetics through Meta-Analysis copy number variant (ENIGMA-CNV) and 22q11.2 Deletion Syndrome Working Groups (22q-ENIGMA WGs) were created to gain insight into the involvement of genetic factors in human brain development and related cognitive, psychiatric and behavioral manifestations. To that end, the ENIGMA-CNV WG has collated CNV and magnetic resonance imaging (MRI) data from ~49,000 individuals across 38 global research sites, yielding one of the largest studies to date on the effects of CNVs on brain structures in the general population. The 22q-ENIGMA WG includes 12 international research centers that assessed over 533 individuals with a confirmed 22q11.2 deletion syndrome, 40 with 22q11.2 duplications, and 333 typically developing controls, creating the largest-ever 22q11.2 CNV neuroimaging data set. In this review, we outline the ENIGMA infrastructure and procedures for multi-site analysis of CNVs and MRI data. So far, ENIGMA has identified effects of the 22q11.2, 16p11.2 distal, 15q11.2, and 1q21.1 distal CNVs on subcortical and cortical brain structures. Each CNV is associated with differences in cognitive, neurodevelopmental and neuropsychiatric traits, with characteristic patterns of brain structural abnormalities. Evidence of gene-dosage effects on distinct brain regions also emerged, providing further insight into genotype–phenotype relationships. Taken together, these results offer a more comprehensive picture of molecular mechanisms involved in typical and atypical brain development. This “genotype-first” approach also contributes to our understanding of the etiopathogenesis of brain disorders. Finally, we outline future directions to better understand effects of CNVs on brain structure and behavior., The ENIGMA Consortium is supported by the NIH Big Data to Knowledge (BD2K) program under consortium grant number U54 EB020403 (PI: Thompson). OAA is supported by the Research Council of Norway, South East Norway Health Authority, KG Jebsen Stiftelsen, EU H2020. C. A. has been funded by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds; European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241,909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603,196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602,478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative two Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso and Fundación Alicia Koplowitz. R. A-A is funded by a Miguel Servet contract from the Carlos III Health Institute (CP18/00003). G. B. is supported by the Dutch Organization for Health Research and Development ZonMw (grants 91112002 & 91712394). A. S. B. is supported by the Dalglish Family Chair in 22q11.2 Deletion Syndrome, Canadian Institutes of Health Research (CIHR) grants MOP-79518, MOP-89066, MOP-97800 and MOP-111238, and NIMH grant number U01 MH101723–01(3/5). C. E. B. is also supported by the National Institute of Mental Health: RO1 MH085953, R01 MH100900 and 1U01MH119736. N. E. B. is granted the KNAW Academy Professor Award (PAH/6635). V. D. C. is supported by NIH R01 MH094524. S. C. is supported by the European Union's Horizon 2020 Framework Programme for Research and Innovation under the Specific Grant Agreement No. 945539 (Human Brain Project SGA3); Helmholtz Initiative and Networking Fund. C. R. K. C. is supported by NIA T32AG058507. E. W. C. C. is supported by the Canadian Institutes of Health Research, Ontario Mental Health Foundation grant MOP-74631 and NIMH grant U01MH101723–01(3/5). S. Ci. has received funding from the European Union's Horizon 2020 Framework Programme for Research and Innovation under the Specific Grant Agreement No. 945539 (Human Brain Project SGA3). M. C. C. is supported by the Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. N. A. C. is supported by Agencia Nacional de Investigación y Desarrollo (ANID Chile) PIA ACT192064. GId. Z. is supported by the NHMRC. J. L. D. and D. E. J. L. are supported by the Wellcome Trust. T. B. C. is supported by NICHD grant PO1-HD070454, NIH grant UO1-MH191719, and NIMH grant R01 MH087636-01A1. AMD is supported by U24DA041147. B. D. is supported by the Swiss National Science Foundation (NCCR Synapsy, project grant numbers 32003B_135679, 32003B_159780, 324730_192755 and CRSK-3_190185), the Leenaards Foundation and the Roger De Spoelberch Foundation. SE is supported by the NARSAD-Young Investigator Grant “Epigenetic Regulation of Intermediate Phenotypes in Schizophrenia”. B. E. S. is supported by the NIH (NIMH). D. C. G. is supported by NIH grant numbers MH078143, MH083824, AG058464. W. R. K. is supported by NIH/MH R0106824. R. E. G. is supported by NIH/NIMH grant numbers MH087626, MH119737. DMMcD-McG is supported by National Institutes of Mental Health (NIMH), grant numbers MH119737-02; MH191719; and MH087636-01A1. S. E. M. is supported by NHMRC grants APP1103623; APP1158127; APP1172917. TM is supported by Research Council of Norway - grant number 273345. D. G. M. is supported by the National Institute for Health Research Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London and EU-AIMS (European Autism Interventions)/EU AIMS-2-TRIALS, a European Innovative Medicines Initiative Joint Undertaking under grant agreements 115300 and 777394. T. N. was supported by Stiftelsen KG Jebsen under grant number SKGJ-MED-021. R. A. O. is supported by NIMH R01 MH090553. S. Y. S. has been funded by the Canadain Institutes of Health Research. M. J. O. is supported by MRC Centre grant MR/L010305/1 and Wellcome Trust grant 100,202/Z/12/Z; Dr. Owen has received research support from Takeda. Z. P. is supported by CIHR, CFI, HSFC. B. G. P. is supported by CIHR FDN 143290 and CAIP Chair. G. M. R. is supported by Fondecyt-Chile #1171014 and ANID-Chile ACT192064. A. Re. was supported by a grant from the Swiss National Science Foundation (31003A_182632). DRR is supported by R01 MH120174 (PI: Roalf). This report represents independent research funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London (to J. J. R). PSS is supported by NHMRC (Australia) program grant 1093083. J. E. S. is supported by NIH K01-ES026840. S. M. S. is supported by the Epilepsy Society. T. J. S. is supported by NIH grants R01MH107108, R01HD042794, and HDU54079125. I. E. S. is supported by South-Eastern Norway Regional Health Authority (#2020060), European Union's Horizon2020 Research and Innovation Programme (CoMorMent project; grant #847776) and the KG Jebsen Foundation (SKGJ-MED-021). V. M. S. is supported by Research Council of Norway (CoE funding scheme, grant number 223273). D. J. S. is supported by the SA MRC. C. K. T. is supported by Research Council of Norway (#230345, #288083, #223273) and South-Eastern Norway Regional Health Authority (#2019069, #2021070, #500189). D. T.-G. was supported by the Instituto de Salud Carlos III (PI14/00639 and PI14/00918) and Fundación Instituto de Investigación Marqués de Valdecilla (NCT0235832 and NCT02534363). Dvd. M. is supported by Research Council of Norway #276082. F. V. R. is supported by the Michael Smith Foundation for Health Research Scholar Award. deCODE genetics has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreements' no. 115008 (NEWMEDS) and no. 115300 (EUAIMS), of which resources are composed of EFPIA in-kind contribution and financial contribution from the European Union's Seventh Framework Programme (EU-FP7/2007–2013). L. T. W. is supported by Research Council of Norway, European Research Council. The IDIVAL neuroimage unit is supported by Instituto de Salud Carlos III PI020499, research funding SCIII-INT13/0014, MICINN research funding SAF2010-20840-C02-02, SAF2013-46292-R. The TOP/NORMENT study are supported by the Research Council of Norway (#223273). The GOBS study data collection was supported in part by the National Institutes of Health (NIH) grants: R01 MH078143, R01 MH078111, and R01 MH083824 with work conducted in part in facilities constructed under the support of NIH grant number C06 RR020547. The Sydney Memory and Ageing Study has been funded by three National Health & Medical Research Council (NHMRC) Program Grants (ID No. ID350833, ID568969, and APP1093083). We thank the participants and their informants for their time and generosity in contributing to this research. We also acknowledge the MAS research team: https://cheba.unsw.edu.au/research-projects/sydney-memory-and-ageing-study. We acknowledge the contribution of the OATS research team (https://cheba.unsw.edu.au/project/older-australian-twins-study) to this study. The OATS study has been funded by a National Health & Medical Research Council (NHMRC) and Australian Research Council (ARC) Strategic Award Grant of the Aging Well, Aging Productively Program (ID No. 401162); NHMRC Project (seed) Grants (ID No. 1024224 and 1025243); NHMRC Project Grants (ID No. 1045325 and 1085606); and NHMRC Program Grants (ID No. 568969 and 1093083). We thank the participants for their time and generosity in contributing to this research. This research was facilitated through access to Twins Research Australia, a national resource supported by a Centre of Research Excellence Grant (ID No. 1079102) from the National Health and Medical Research Council. The NCNG sample collection was supported by grants from the Bergen Research Foundation and the University of Bergen, the Dr Einar Martens Fund, the KG Jebsen Foundation, the Research Council of Norway, to S. L. H., V. M. S., A. J. L., and T. E. The authors thank Dr. Eike Wehling for recruiting participants in Bergen, and Professor Jonn-Terje Geitung and Haraldplass Deaconess Hospital for access to the MRI facility. Additional support by RCN grants 177458/V50 and 231286/F20. The Betula study was supported by a Wallenberg Scholar Grant (KAW). The HUNT Study is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU—Norwegian University of Science and Technology), Nord-Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health. HUNT-MRI was funded by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology, and the Norwegian National Advisory Unit for functional MRI. Research for the GAP cohort was supported by the Department of Health via the National Institute for Health Research (NIHR) Specialist Biomedical Research Center for Mental Health award to South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry at King's College London, London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. S.J. is supported by Calcul Quebec (http://www.calculquebec.ca), Compute Canada (http://www.computecanada.ca), the Brain Canada Multi investigator research initiative (MIRI), the Institute of Data Valorization (Canada First Research Excellence Fund), CHIR, Canada Research Chairs and the Jeanne et Jean Louis Levesque Foundation. The NTR cohort was supported by the Netherlands Organization for Scientific Research (NWO), MW904-61-193 (de Geus & Boomsma), MaGWnr: 400-07-080 (van 't Ent), MagW 480-04-004 (Boomsma), NWO/SPI 56-464-14,192 (Boomsma), the European Research Council, ERC-230374 (Boomsma), and Amsterdam Neuroscience. Funding for genotyping was obtained from the National Institutes of Health (NIMH U24 MH068457-06; Grand Opportunity grants 1RC2 MH089951, and 1RC2 MH089995); the Avera Institute for Human Genetics, Sioux Falls, South Dakota (USA). Part of the genotyping and analyses were funded by the Genetic Association Information Network (GAIN) of the Foundation for the National Institutes of Health. The Brainscale study was supported by the Netherlands Organization for Scientific Research MagW 480-04-004 (Boomsma), 51.02.060 (Hilleke Hulshoff Pol), 668.772 (Boomsma & Hulshoff Pol); NWO/SPI 56-464-14192 (Boomsma), the European Research Council (ERC230374) (Boomsma), High Potential Grant Utrecht University (Hulshoff Pol), NWO Brain and Cognition 433-09-220 (Hulshoff Pol). SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs and the Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide SNP typing in SHIP and MRI scans in SHIP and SHIP-TREND have been supported by a joint grant from Siemens Healthcare, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania. The ENIGMA-22q11.2 Deletion Syndrome Working Group wishes to acknowledge our dear colleague Dr. Clodagh Murphy, who sadly passed away in April 2020. Open access funding enabled and organized by Projekt DEAL., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Exploring the Impact of Schizophrenia and Its Pharmacological Treatment on Health-Related Quality of Life and Treatment Preferences

  • Arango, Celso
  • Baeza, Inmaculada
  • García-Rizo, Clemente
  • Crespo-Facorro, Benedicto
  • Lahera, Guillermo
  • Vieta, Eduard
  • Becker, Frauke
  • Dwyer, Georges
  • Bourke, Siobhan
  • Gibson, Adam
  • Gabarda-Inat, Irene
  • Álvarez-Baron, Elena
The abstract of this paper was presented at the 36th ECNP Congress 2023 (Barcelona 7-10 October) as a poster presentation with interim findings. The poster’s abstract was published in Abstracts of the 36th ECNP Congress 2023 in Neuroscience applied (Vol2, Supplement 2): https://doi.org/10.1016/j.nsa.2023.103062., [Purpose:] Pharmacological treatments play an important role in managing symptoms of schizophrenia but can also be associated with side effects. The aim of this study was to understand the impact of schizophrenia and its pharmacological treatment on patients’ health-related quality of life (HRQoL) and to explore patient preferences around treatment benefits and side effects., [Patients and Methods:] This study employed a mixed methods approach with two stages of recruitment of adult patients in Spain. Stage 1 included qualitative and quantitative elements (including included two validated patient-reported outcome measures: PETiT and EQ-5D-5L) administered in telephone interviews with people with schizophrenia. Stage 2 consisted of a quantitative online survey completed by people with schizophrenia attending outpatient clinics. Responses to quantitative items across both stages were combined for analysis., [Results:] Twenty respondents completed the mixed methods interviews (stage 1), and 25 participants completed the online survey (stage 2). Results from stages 1 and 2, showed that participants perceived treatments to have a beneficial impact on controlling their symptoms. However, cognitive side effects were reported to have a detrimental impact on respondents’ daily life and were considered a primary reason for treatment cessation in the past. Qualitative findings further showed that most participants hoped future treatments would minimise the impact of cognitive symptoms of schizophrenia., [Conclusion:] The findings suggest that patients’ expectation around treatment efficacy and their acceptability of treatment side effects may indicate their capacity to maintain long-term treatment adherence. Trade-offs that patients may be willing to make between these components may prove useful to consider in clinical practice to improve treatment adherence and hence treatment effectiveness in people with schizophrenia., CA has been supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, financed by the European Union - NextGenerationEU (PMP21/00051), PI19/01024, PI22-01824.CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz. IB has been supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (PI21/0391), co-financed by the European Union, Drugs National Plan (2022I053) and Fundación Alicia Koplowitz., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Penetrance of neurodevelopmental copy number variants is associated with variations in cortical morphology

  • Silva, Ana I.
  • Crespo-Facorro, Benedicto
  • Tordesillas-Gutiérrez, Diana
  • Linden, David E. J.
  • ENIGMA-CNV Working Group
ENIGMA-CNV Working Group: et al, [Background] Copy number variants (CNVs) may increase the risk for neurodevelopmental conditions. The neurobiological mechanisms that link these high-risk genetic variants to clinical phenotypes are largely unknown. An important question is whether brain abnormalities in individuals who carry CNVs are associated with their degree of penetrance., [Methods] We investigated whether increased CNV penetrance for schizophrenia and other developmental disorders was associated with variations in cortical and subcortical morphology. We pooled T1-weighted brain magnetic resonance imaging and genetic data from 22 cohorts from the ENIGMA (Enhancing Neuro Imaging Genetics through Meta Analysis)-CNV consortium. In the main analyses, we included 9268 individuals (aged 7–90 years, 54% female), from which we identified 398 carriers of 36 neurodevelopmental CNVs at 20 distinct loci. A secondary analysis was performed including additional neuroimaging data from the ENIGMA-22q consortium, including 274 carriers of the 22q11.2 deletion and 291 noncarriers. CNV penetrance was estimated through penetrance scores that were previously generated from large cohorts of patients and controls. These scores represent the probability risk of developing either schizophrenia or other developmental disorders (including developmental delay, autism spectrum disorder, and congenital malformations)., [Results] For both schizophrenia and developmental disorders, increased penetrance scores were associated with lower surface area in the cerebral cortex and lower intracranial volume. For both conditions, associations between CNV-penetrance scores and cortical surface area were strongest in regions of the occipital lobes, specifically in the cuneus and lingual gyrus., [Conclusions] Our findings link global and regional cortical morphometric features with CNV penetrance, providing new insights into neurobiological mechanisms of genetic risk for schizophrenia and other developmental disorders., 16p11.2 Consortium: This work was supported by Compute Canada, the Brain Canada Multi investigator research initiative, Canada First Research Excellence Fund, the Institute of Data Valorization, and Healthy Brain Healthy Lives. SJ is a recipient of a Canada Research Chair in neurodevelopmental disorders and a chair from the Jeanne et Jean Louis Levesque Foundation. This work was supported by the Canadian Institutes of Health Research (CIHR) (Grant Nos. 400528 and 438531) and Innovative Medicines Initiative 2 Joint Undertaking (Grant No. 777394) for AIMS-2-TRIALS. This Joint Undertaking receives support from the EU’s Horizon 2020 program, EFPIA, Autism Speaks, Autistica, and SFARI. KK was supported by The Institute of Data Valorization Postdoctoral Fellowship program, through the Canada First Research Excellence Fund. COBRE (Centers of Biomedical Research Excellence): This research is funded by National Science Foundation (Grant No. 2112455) and National Institutes of Health (NIH) (Grant No. R01MH118695). Dublin: This research is funded by European Research Council (Grant No. 677467). ECHO-DEFINE: The ECHO (Experiences of Children with Copy Number Variants) study acknowledges funding from the Wellcome Trust (Institutional Strategic Support Fund) (to MBMvdB) and Clinical Research Training Fellowship (Grant No. 102003/Z/13/Z [to JLD]), the Waterloo Foundation (Grant No. WF 918- 1234 [to MBMvdB]), the Baily Thomas Charitable Fund (Grant No. 2315/1 [to MBMvdB]), National Institute of Mental Health (NIMH) (Grant No. 5UO1MH101724) and NIMH (Grant No. U01MH119738 [to MBMvdB]), the IMAGINE-ID and IMAGINE-2 studies (funded by Medical Research Council [MRC]) (Grant Nos. MR/N022572/1 and MR/T033045/1 [to MBMvdB]) and an MRC Centre Grant (Grant No. MR/P005748/1 [to MJO]). The DEFINE (Defining Endophenotypes From Integrative Neuroscience) study was supported by a Wellcome Trust Strategic Award (Grant No. 100202/Z/12/Z [to MJO]). ENIGMA: The ENIGMA Working Group acknowledges the NIH Big Data to Knowledge award for foundational support and consortium development (Grant No. U54 EB020403 [to PMT]). For a complete list of ENIGMA-related grant support, please see here: http://enigma.ini.usc.edu/about-2/funding/. PMT and SIT are also supported in part by ENIGMA NIH (Grant Nos. R01MH116147, R01NS107513, R01AG058854, and R01MH129742). IES is supported by the Research Council of Norway (Grant No. 223273), South-Eastern Norway Regional Health Authority (Grant No. 2020060), European Union’s Horizon2020 Research and Innovation Programme (CoMorMent project) (Grant No. 847776), and Kristian Gerhard Jebsen Stiftelsen (Grant No. SKGJ-MED-021). South-Eastern Norway Regional Health Authority (Grant No. 2020060) also supports RBo. This work was partially performed on Services for Sensitive Data (TSD), University of Oslo, Norway, with resources provided by UNINETT Sigma2, the National Infrastructure for High Performance Computing and Data Storage in Norway. OAA is supported by Research Council of Norway (Grant No. 223273) and KG Jebsen Stiftelsen (Grant No. SKGJ-MED-021). NJ is supported by NIH (Grant No. R01MH117601). DvdM is supported by Research Council of Norway (Grant No. 276082). ENIGMA-22q: This research is supported by NIMH (Grant Nos. R01MH085953, R21MH116473, and 9U01MH119736-02). ASB is supported by the Dalglish Family Chair in 22q11.2 Deletion Syndrome, CIHR (Grant Nos. MOP-79518, MOP-89066, MOP-97800, and MOP-111238) and NIMH (Grant No. U01MH101723–01[3/5]). EWCC acknowledges support from the CIHR (Grant No. MOP-74631) and Ontario Mental Health Foundation for the current work. DRR is supported by NIMH (Grant No. R01 119185). JES is supported by the Stanford Maternal and Child Health Research Institute Uytengsu-Hamilton 22q11 Neuropsychiatry Research Awards Program (Grant No. UH22QEXTFY21). DMM-M acknowledges support from NIMH (Grant No. U01MH119737). JASV acknowledges funding support from NIMH (Grant Nos. 1U01MH119741-01 and 3U01MH119741-02S1). TvA acknowledges financial support from NIMH (Grant No. 5U01 MH119740). GAP: PD’s research is supported by the MRC and the Wellcome Trust. Funding was received from the Psychiatry Research Trust, the Wellcome Trust, the MRC, and the National Institute for Health Research (NIHR) Biomedical Research Centre at the South London and Maudsley NHS Trust. The funding sources were not involved in carrying out or interpreting the study. GOBS: The GOBS (Genetics of Brain Structure and Function study) data collection was supported in part by NIH (Grant Nos. R01MH078143 and R01MH083824). Haavik: This research is supported by Stiftelsen KG Jebsen (Grant No. SKGJ MED-02), the Research Council of Norway, and Helse Vest RHF. HUBIN (Human Brain Informatics): This research is supported by Swedish Research Council (Grant Nos. K2007-62X-15077-04-1, K2008-62P-20597-01-3, K2010-62X-15078-07-2, K2012-61X-15078-09-3, K2015-62X-15077-12-3, and 2017-00949), the regional agreement on medical training and clinical research between Stockholm County Council and the Karolinska Institutet, and the Research Council of Norway (Grant No. 274 359). HUNT: The HUNT (Trøndelag Health Study) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology), North Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health. HUNT-MRI was funded by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology and the Norwegian National Advisory Unit for functional MRI. IMAGEN: The European Union–funded FP6 Integrated Project IMAGEN (Reinforcement-related behavior in normal brain function and psychopathology) (Grant No. LSHM-CT- 2007-037286), the Horizon 2020 funded ERC Advanced Grant STRATIFY (Brain network based stratification of reinforcement-related disorders) (Grant No. 695313), Human Brain Project (Grant Nos. HBP SGA 2, 785907, and HBP SGA 3, 945539), the MRC Grant c-VEDA (Consortium on Vulnerability to Externalizing Disorders and Addictions) (Grant No. MR/N000390/1), NIH (Grant No. R01DA049238), A decentralized macro and micro gene-by-environment interaction analysis of substance use behavior and its brain biomarkers), the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London, the Bundesministerium für Bildung und Forschung (Grant Nos. 01GS08152; 01EV0711; Forschungsnetz AERIAL 01EE1406A, 01EE1406B; Forschungsnetz IMAC- Mind 01GL1745B), the Deutsche Forschungsgemeinschaft (DFG Grant Nos. SM 80/7-2, SFB 940, TRR 265, NE 1383/14-1), ImagenPathways “Understanding the Interplay between Cultural, Biological and Subjective Factors in Drug Use Pathways” is a collaborative project supported by the European Research Area Network on Illicit Drugs, the Medical Research Foundation and MRC (Grant Nos. MR/R00465X/1 and MR/S020306/1), the NIH-funded ENIGMA (Grant Nos. 5U54EB020403-05 and 1R56AG058854-01), National Natural Science Foundation of China (NSFC) (Grant No. 82 150 710 554), and European Union–funded project environMENTAL (Grant No. 101057429). Additional support was provided by grants from the ANR (Grant Nos. ANR-12-SAMA-0004, AAPG2019—GeBra), the Eranet Neuron (Grant Nos. AF12-NEUR0008-01—WM2NA; and ANR-18-NEUR00002-01—ADORe), the Fondation de France (Grant No. 00081242), the Fondation pour la Recherche Médicale (Grant No. DPA20140629802), the Mission Interministérielle de Lutte-contre-les-Drogues-et-les-Conduites-Addictives, the Assistance Publique-Hôpitaux de Paris and Institut National de la Santé et de la Recherche Médicale (INSERM) (interface grant), Paris Sud University IDEX 2012, the Fondation de l’Avenir (Grant No. AP-RM-17-013), the Fédération pour la Recherche sur le Cerveau; the NIH, Science Foundation Ireland (Grant No. 16/ERCD/3797), the Science Foundation Ireland (Grant No. 16/ERCD/3797), the NIH (Axon, Testosterone and Mental Health during Adolescence) (Grant No. R01MH085772-01A1), and the NIH Consortium (Grant No. U54 EB020403), supported by a cross-NIH alliance that funds Big Data to Knowledge Centres of Excellence. The INSERM, the Strasbourg University, and SATT CONECTUS, provided sponsorship (principal investigator: J-LM). TP is supported by NIH (Grant No. R01MH085772). Gilles Berstchy is acknowledged for his support. Stephane Lehericy and the radiographer staff at Centre de NeuroImagerie de Recherche de l'’Institut du Cerveau (http://www.cenir.org/mri.html?lang=en) are acknowledged for their support in acquisition of MRI datasets. MCIC (Mind Clinical Imaging Consortium): This research is funded by NIH study P20GM103472. METH-CT: DJS is supported by the South African Medical Research Council (SAMRC). FS is supported by a PDRF (Presidential Doctoral Research Fellowship) from the Brain Behavior Unit, Department of Psychiatry and Mental Health, University of Cape Town. SD is supported by the Biomedical Research and Innovation Platform and SAMRC. NCNG: NCNG (Norwegian Cognitive NeuroGenetics sample) was supported by the Bergen Research Foundation, the University of Bergen, the Research Council of Norway (FUGE) (Enhance Research in Functional Genomics) (Grant Nos. 151904 and 183327), Psykisk Helse (Grant No. 175345), RCN (Grant Nos. 154313/V50 [to Ivar Reinvang] and 177458/V50 [to TE]), Helse SørØst RHF (Grant No. 2012086 [to TE]), and the Dr. Einar Martens Fund. NTR: The NTR cohort was supported by the Netherlands Organization for Scientific Research (NWO) and The Netherlands Organization for Health Research and Development (ZonMW) (Grant Nos. 904-61-090, 985-10-002, 912-10-020, 904-61-193, 480-04-004, 463-06-001, 451-04-034, 400-05-717, Addiction-31160008, 016-115-035, 481-08-011, 400-07-080, 056-32-010, Middelgroot-911-09-032, OCW_NWO Gravity program –024.001.003, NWO-Groot 480-15-001/674), Center for Medical Systems Biology (CMSB, NWO Genomics), NBIC/BioAssist/RK(2008.024), Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) (Grant Nos. NL, 184.021.007 and 184.033.111), X-Omics 184-034-019; Spinozapremie (Grant No. NWO- 56-464-14192), KNAW Academy Professor Award (PAH/6635) and University Research Fellow grant (to DIB); Amsterdam Public Health Research Institute (former EMGO+), Neuroscience Amsterdam research institute (former NCA); the European Community’s Fifth and Seventh Framework Program (Grant Nos. FP5- LIFE QUALITY-CT-2002-2006, FP7-HEALTH-F4-2007-2013, Grant No. 01254: GenomEUtwin, Grant No. 01413: ENGAGE and Grant No. 602768:ACTION); the European Research Council (Grant Nos. ERC Starting 284 167, ERC Consolidator 771057, ERC Advanced 230374), Rutgers University Cell and DNA Repository (NIMH) (Grant No. U24 MH068457-06), NIH (Grant Nos. R01D0042157-01A1, R01MH58799-03, MH081802, DA018673, R01DK092127-04), Grand Opportunity (Grant Nos. 1RC2 MH089951 and 1RC2 MH089995); and the Avera Institute for Human Genetics, Sioux Falls, South Dakota. Part of the genotyping and analyses were funded by the Genetic Association Information Network of the Foundation for the NIH. Computing was supported by NWO (Grant No. 2018/EW/00408559), BiG Grid, the Dutch e-Science Grid, and SURFSARA. OATS1/OATS2 and Sydney MAS: The OATS (Older Australian Twins Study) has been funded by a National Health & Medical Research Council (NHMRC) and Australian Research Council (ARC) Strategic Award Grant of the Ageing Well, Ageing Productively Program (Grant No. 401162); NHMRC Project (seed) Grants (Grant Nos. 1024224 and 1 025 243); NHMRC Project Grants (Grant Nos. 1045325 and 1085606); and NHMRC Program Grants (Grant Nos. 568969 and 1093083). This research was facilitated through access to Twins Research Australia, which is a national resource supported by a Centre of Research Excellence Grant (Grant No. 1079102) from the NHMRC. The Sydney Memory and Ageing Study has been funded by 3 NHMRC Program Grants (Grant Nos. ID350833, ID568969, and APP1093083). Core funding was received from the NSW Government Department of Health and the Australian government Department of Health and Aged Care; NHMRC Leadership Fellowship (Grant No. GNT2009771); NHMRC (Grant No. GNT1045325). DNA samples were extracted by Genetic Repositories Australia, an Enabling Facility, which was supported by an NHMRC Grant (Grant No. 401184). MRI scans were processed with the support of NHMRC Project Grants (Grant Nos. 510175 and 1025243) and an ARC Discovery Project Grant (Grant No. DP0774213) and John Holden Family Foundation. PAFIP: This study was supported by grants from Carlos III Health Institute (Grant Nos. IPI17/00402, PI17/01056, PI14/00639, and PI14/00918) cofunded by the European Union through FEDER funds and Fundación Instituto de Investigación Marqués de Valdecilla (Grant Nos. NCT0235832 and NCT02534363). No pharmaceutical company has financially supported the study. JV-B acknowledges IDIVAL Grants (Grant Nos. INT/A21/10 and INT/A20/04). QTIM: The QTIM study was supported by grants from the U.S. National Institute of Child Health and Human Development (Grant No. R01HD050735) and the Australian NHMRC (Grant Nos. 486682, 1009064). Genotyping was supported by NHMRC (Grant No. 389875). AFM is funded by an ARC Future Fellowship (Grant No. FT200100837). SEM is supported by NHMRC Investigator Grant (Grant No. APP1172917). SHIP-2/SHIP-TREND: SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (Grant Nos. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network “Greifswald Approach to Individualized Medicine (GANI_MED)” funded by the Federal Ministry of Education and Research (Grant No. 03IS2061A). Genome-wide data have been supported by the Federal Ministry of Education and Research (Grant No. 03ZIK012) and a joint grant from Siemens Healthineers and the Federal State of Mecklenburg-West Pomerania. The University of Greifswald is a member of the Caché Campus program of the InterSystems GmbH. This study has received funding from the following institutions: Federal Ministry of Education and Research, the Ministry of Cultural Affairs, as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania. MRI examinations were supported by Siemens Healthineers, Siemens Healthcare GmbH. AT has been funded by DFG (Grant No. 542489987). The SHIP authors thank Holger Prokisch and Thomas Meitinger (Helmholtz Zentrum München) for the genotyping of the SHIP-TREND cohort. Stroke (TOP_T3): The European Research Council under the European Union’s Horizon 2020 research and Innovation program (Grant No. ERC 802998). The Research Council of Norway (Grant Nos. 298646 and 300767), and the South-Eastern Norway Regional Health Authority (Grant Nos. 2013054, 2015044, 2015073, 2018076, 2019101, and 2020060)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Biological underpinnings and genetic predisposition to schizophrenia within microrna-137 regulatory pathways across brain development

  • Stella, Carol
  • Hoyos, Lucía de
  • Mora, Alberto
  • Díaz-Caneja, Covadonga M.
  • Andreu-Bernabeu, Álvaro
  • Costas, Javier
  • Gurriarán, Xaquín
  • Fañanas, Lourdes
  • Bobes, Julio
  • González-Pinto, Ana
  • Crespo-Facorro, Benedicto
  • Vázquez-Bourgon, Javier
  • Martorell, Lourdes
  • Vilella, Elisabet
  • Muntané, Gerard
  • Sánchez-Gistau, Vanessa
  • Moltó, Maria Dolores
  • Rivero, Olga
  • CIBERSAM consortium
  • Arango, Celso
  • González-Peñas, Javier
[Data availability] GWAS summary datasets used in this study have been downloaded from the PGC repository (https://www.med.unc.edu/pgc/download-results/). Gene expression data from brain developmental trajectories (http://www.brainspan.org/) and adult brain (https://gtexportal.org/home/) were downloaded from FUMA platform (https://fuma.ctglab.nl/). Individual genotype data for the CIBERSAM consortium samples (Spain, https://www.cibersam.es/en) used here and analytic code are available from the corresponding author upon reasonable request, since deposit of this data to a public repository is not allowed due to ethical and legal requirements at the participating centers., Previous studies have evaluated the role of the microRNA-137 (miRNA137) regulatory pathway in schizophrenia by using in silico or in vitro predicted target genes. These approaches do not capture the dynamic spatiotemporal nature of the miRNA137 regulatory pathway or tend to overestimate direct miRNA binding sites. To provide a more accurate representation of the miRNA137 pathway during human brain development, we evaluated the biological functionality of direct ex vivo miRNA137 targets previously documented in the early prenatal and adult brain. We studied the role of differential expression and genetic predisposing variation to schizophrenia and related disorders within these miRNA137 targets by gene set enrichment analyses (GSEA) and gene-set based polygenic score predictions in an independent schizophrenia case-control cohort. All results were compared to those from in silico or in vitro predicted targets. Only direct miRNA137 targets at prenatal and adult human brain displayed significant enrichments in synaptic and neuronal functions and captured the transcriptomic and genetic predisposing variation to schizophrenia. Furthermore, while adult target genes showed a more consistent enrichment in predisposing variation to schizophrenia and bipolar disorder in case/control polygenic models, prenatal target genes predicted negative symptomatology in schizophrenia patients. Our results suggest that using direct, temporally specific miRNA137 targets significantly improved the detection of biological mechanisms underlying its relationship with psychosis, clarified the association between schizophrenia and related conditions, and suggested association with specific symptomatology domains at different developmental stages of the disorder., Supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB/07/09/0023), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, (SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, PI20/00721, PI22/01824, PI23/00625), the European Union -NextGenerationEU (PMP21/00051), Madrid Regional Government (S2022/BMD-7216 AGES 3-CM), European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394)) European Union Horizon Europe Program (Project Youth-GEMs (Grant agreement No 101057182), the National Institute of Mental Health of the National Institutes of Health, Fundación Familia Alonso, and Fundación Alicia Koplowitz. González-Peñas held a Sara Borrell and a Miguel Servet grant during the development of the research from Instituto de Salud Carlos III (CD20/00118; CP24/00080-DOS). CM Díaz-Caneja has previously held a Juan Rodés Grant from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (JR19/00024)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis

  • Solanes, Aleix
  • Mezquida, Gisela
  • Janssen, Joost
  • Amoretti, Silvia
  • Lobo, Antonio
  • González-Pinto, Ana
  • Arango, Celso
  • Vieta, Eduard
  • Castro-Fornieles, Josefina
  • Bergé, Daniel
  • Albacete, Auria
  • Giné, Eloi
  • Parellada, Mara
  • Bernardo, Miguel
  • Bioque, Miquel
  • Morén, Constanza
  • Pina-Camacho, Laura
  • Díaz-Caneja, Covadonga M.
  • Zorrilla, Iñaki
  • Corres, Edurne Garcia
  • De-La-Camara, Concepción
  • Barcones, Fe
  • Escarti, María José
  • Aguilar, Eduardo Jesus
  • Legido, Teresa
  • Martin, Marta
  • Verdolini, Norma
  • Martinez-Aran, Anabel
  • Baeza, Immaculada
  • de la Serna, Elena
  • Contreras, Fernando
  • Bobes, Julio
  • García-Portilla, María Paz
  • Sanchez-Pastor, Luis
  • Rodriguez-Jimenez, Roberto
  • Usall, Judith
  • Butjosa, Anna
  • Salgado-Pineda, Pilar
  • Salvador, Raymond
  • Pomarol-Clotet, Edith
  • Radua, Joaquim
Detecting patients at high relapse risk after the first episode of psychosis (HRR-FEP) could help the clinician adjust the preventive treatment. To develop a tool to detect patients at HRR using their baseline clinical and structural MRI, we followed 227 patients with FEP for 18–24 months and applied MRIPredict. We previously optimized the MRI-based machine-learning parameters (combining unmodulated and modulated gray and white matter and using voxel-based ensemble) in two independent datasets. Patients estimated to be at HRR-FEP showed a substantially increased risk of relapse (hazard ratio = 4.58, P < 0.05). Accuracy was poorer when we only used clinical or MRI data. We thus show the potential of combining clinical and MRI data to detect which individuals are more likely to relapse, who may benefit from increased frequency of visits, and which are unlikely, who may be currently receiving unnecessary prophylactic treatments. We also provide an updated version of the MRIPredict software.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Cortical thinning over two years after first-episode psychosis depends on age of onset

  • Pina-Camacho, Laura
  • Martinez, Kenia
  • Diaz-Caneja, Covadonga M.
  • Mezquida, Gisela
  • Cuesta, Manuel J.
  • Moreno, Carmen
  • Amoretti, Silvia
  • González-Pinto, Ana
  • Arango, Celso
  • Vieta, Eduard
  • Castro-Fornieles, Josefina
  • Lobo, Antonio
  • Fraguas, David
  • Bernardo, Miguel
  • Janssen, Joost
  • Parellada, Mara
  • Madero, Santiago
  • Gómez-Ramiro, Marta
  • Rodriguez-Toscano, Elisa
  • Santonja, Javier
  • Zorrilla, Iñaki
  • González-Ortega, Itxaso
  • Fayed, Nicolás
  • Santabárbara, Javier
  • Berge, Daniel
  • Toll, Alba
  • Nacher, Juan
  • García Martí, Gracián
  • Sague-Vilavella, Maria
  • Sanchez-Moreno, Jose
  • de la Serna, Elena
  • Baeza, Immaculada
  • Saiz-Masvidal, Cristina
  • Contreras, Fernando
  • González-Blanco, Leticia
  • Bobes-Bascarán, Teresa
  • Dompablo, Mónica
  • Rodriguez-Jimenez, Roberto
  • Usall, Judith
  • Butjosa, Anna
  • Pomarol-Clotet, Edith
  • Sarró, Salvador
First-episode psychosis (FEP) patients show structural brain abnormalities at the first episode. Whether the cortical changes that follow a FEP are progressive and whether age at onset modulates these changes remains unclear. This is a multicenter MRI study in a deeply phenotyped sample of 74 FEP patients with a wide age range at onset (15–35 years) and 64 neurotypical healthy controls (HC). All participants underwent two MRI scans with a 2-year follow-up interval. We computed the longitudinal percentage of change (PC) for cortical thickness (CT), surface area (CSA) and volume (CV) for frontal, temporal, parietal and occipital lobes. We used general linear models to assess group differences in PC as a function of age at FEP. We conducted post-hoc analyses for metrics where PC differed as a function of age at onset. We found a significant age-by-diagnosis interaction effect for PC of temporal lobe CT (d = 0.54; p = 002). In a post-hoc-analysis, adolescent-onset (≤19 y) FEP showed more severe longitudinal cortical thinning in the temporal lobe than adolescent HC. We did not find this difference in adult-onset FEP compared to adult HC. Our study suggests that, in individuals with psychosis, CT changes that follow the FEP are dependent on the age at first episode, with those with an earlier onset showing more pronounced cortical thinning in the temporal lobe.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

La psiquiatría post-COVID-19

  • Vieta, Eduard
  • Pérez Solà, Víctor
  • Arango, Celso
EV would like to thank the Ministry of Science and Research (PI15/00283, PI18/00805) integrated in the National R+D+I Plan and co-financed by the ISCIII-General Subdirectorate of Evaluation and the European Regional Development Fund (ERDF), the Commission for Universities and Research, Department of Innovation, Universities, and Business (DIUE), Government of Catalonia (2017 SGR 1365), and project SLT006/17/00357 of the Strategic Plan for Health Research and Innovation (PERIS) 2016–2020 (Department of Health), CERCA PROGRAM, Government of Catalonia. VP would like to thank the Ministry of Science and Research (PI19/00236) integrated in the National R+D+I Plan and co-financed by the ISCIII-General Subdirectorate of Evaluation and the European Regional Development Fund (ERDF), CIBERSAM G21. Commission for Universities and Research, Department of Innovation, Universities, and Business (DIUE), Government of Catalonia (2017 SGR 134), CERCA Program, Government of Catalonia. CA has received support from the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by the European Commission's ERDF Fund, “A way of making Europe,” CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No. 115916, Project PRISM, and grant agreement No. 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, and Fundación Alicia Koplowitz.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Neonatal brain dynamic functional connectivity in term and preterm infants and its association with early childhood neurodevelopment

  • França, Lucas G. S.
  • Deco, Gustavo
  • Batalle, Dafnis
Brain dynamic functional connectivity characterises transient connections between brain regions. Features of brain dynamics have been linked to emotion and cognition in adult individuals, and atypical patterns have been associated with neurodevelopmental conditions such as autism. Although reliable functional brain networks have been consistently identified in neonates, little is known about the early development of dynamic functional connectivity. In this study we characterise dynamic functional connectivity with functional magnetic resonance imaging (fMRI) in the first few weeks of postnatal life in term-born (n = 324) and preterm-born (n = 66) individuals. We show that a dynamic landscape of brain connectivity is already established by the time of birth in the human brain, characterised by six transient states of neonatal functional connectivity with changing dynamics through the neonatal period. The pattern of dynamic connectivity is atypical in preterm-born infants, and associated with atypical social, sensory, and repetitive behaviours measured by the Quantitative Checklist for Autism in Toddlers (Q-CHAT) scores at 18 months of age. © The Author(s) 2024., This work was supported by the European Research Council under the European Union's Seventh Framework Programme (FP7/20072013)/ERC grant agreement no. 319456 (dHCP project) and a Wellcome Trust Seed Award in Science [217316/Z/19/Z] to DB. This study represents independent research part funded by the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King's College London. The authors also acknowledge support in part from the Engineering and Physical Sciences Research Council (EPSRC) Centre for Medical Engineering at Kings College London [WT 203148/Z/16/Z], MRC strategic grant [MR/K006355/1], the Department of Health through an NIHR Comprehensive Biomedical Research Centre Award (to King's College Hospital NHS Foundation Trust). The results leading to this publication have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777394 for the project AIMS-2-TRIALS. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI. S.F.M. and O.G.G. were supported by grants from the UK Medical Research Council [MR/N013700/1] and [MR/P502108/1] respectively. J.O.M., T.A., G.M., and A.D.E. received support from the Medical Research Council Centre for Neurodevelopmental Disorders, King's College London [MR/N026063/1]. L.C.-G. received support from Project PID2021-129022OA-I00 funded by MCIN/AEI/10.13039/501100011033/FEDER, EU, and CAM-Spain under the line support for R&D projects for Beatriz Galindo researchers BGP18/00178. J.J.T. was supported by grants from the Finnish Medical Foundation, Sigrid Juselius Foundation, Signe and Ane Gyllenberg Foundation, Emil Aaltonen Foundation and Hospital District of Southwest Finland State Research Grants. J.O.M. is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society [206675/Z/17/Z]. T.A. is supported by an MRC Clinician Scientist Fellowship [MR/P008712/1] and Transition Support Award [MR/V036874/1]. The authors acknowledge use of the research computing facility at King's College London, Rosalind (https://rosalind.kcl.ac.uk), which is delivered in partnership with the National Institute for Health Research (NIHR) Biomedical Research Centres at South London & Maudsley and Guy's & St. Thomas' NHS Foundation Trusts, and part-funded by capital equipment grants from the Maudsley Charity (award 980) and Guy's & St. Thomas' Charity (TR130505). The views expressed are those of the authors and not necessarily those of the funders, the NHS, the National Institute for Health Research, the Department of Health and Social Care, or the IHI-JU2. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Altered structural brain asymmetry in autism spectrum disorder in a study of 54 datasets

  • Postema, Merel C.
  • van Rooij, Daan
  • Anagnostou, Evdokia
  • Arango, Celso
  • Auzias, Guillaume
  • Behrmann, Marlene
  • Filho, Geraldo Busatto
  • Calderoni, Sara
  • Calvo Escalona, Rosa
  • Daly, Eileen
  • Deruelle, Christine
  • Di Martino, Adriana
  • Dinstein, Illan
  • Duran, Fabio Luis S.
  • Durston, Sarah
  • Ecker, Christine
  • Ehrlich, Stefan
  • Fair, Damien
  • Fedor, Jennifer
  • Feng, Xin
  • FitzGerald, Jackie
  • Floris, Dorothea L.
  • Freitag, Christine M.
  • Gallagher, Louise
  • Glahn, David C.
  • Gori, Ilaria
  • Haar, Shlomi
  • Hoekstra, Liesbeth
  • Jahanshad, Neda
  • Jalbrzikowski, Maria
  • Janssen, Joost
  • King, Joseph A.
  • Kong, Xiang-Zhen
  • Lázaro García, Luisa
  • Lerch, Jason P.
  • Luna, Beatriz
  • Martinho, Mauricio M.
  • McGrath, Jane
  • Medland, Sarah E.
  • Muratori, Filippo
Altered structural brain asymmetry in autism spectrum disorder (ASD) has been reported. However, findings have been inconsistent, likely due to limited sample sizes. Here we investigated 1,774 individuals with ASD and 1,809 controls, from 54 independent data sets of the ENIGMA consortium. ASD was significantly associated with alterations of cortical thickness asymmetry in mostly medial frontal, orbitofrontal, cingulate and inferior temporal areas, and also with asymmetry of orbitofrontal surface area. These differences generally involved reduced asymmetry in individuals with ASD compared to controls. Furthermore, putamen volume asymmetry was significantly increased in ASD. The largest case-control effect size was Cohen's d = -0.13, for asymmetry of superior frontal cortical thickness. Most effects did not depend on age, sex, IQ, severity or medication use. Altered lateralized neurodevelopment may therefore be a feature of ASD, affecting widespread brain regions with diverse functions. Large-scale analysis was necessary to quantify subtle alterations of brain structural asymmetry in ASD.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis

  • Solanes, Aleix
  • Mezquida, Gisela
  • Janssen, Joost
  • Amoretti, Silvia
  • Lobo, Antonio
  • González-Pinto, Ana
  • Arango, Celso
  • Vieta, Eduard
  • Castro-Fornieles, Josefina
  • Bergé, Daniel
  • Albacete, Auria
  • Giné, Eloi
  • Parellada, Mara
  • Bernardo, Miquel
  • PEPs Group
  • Pomarol-Clotet, Edith
  • Radua, Joaquim
Detecting patients at high relapse risk after the first episode of psychosis (HRR-FEP) could help the clinician adjust the preventive treatment. To develop a tool to detect patients at HRR using their baseline clinical and structural MRI, we followed 227 patients with FEP for 18-24 months and applied MRIPredict. We previously optimized the MRI-based machine-learning parameters (combining unmodulated and modulated gray and white matter and using voxel-based ensemble) in two independent datasets. Patients estimated to be at HRR-FEP showed a substantially increased risk of relapse (hazard ratio = 4.58, P < 0.05). Accuracy was poorer when we only used clinical or MRI data. We thus show the potential of combining clinical and MRI data to detect which individuals are more likely to relapse, who may benefit from increased frequency of visits, and which are unlikely, who may be currently receiving unnecessary prophylactic treatments. We also provide an updated version of the MRIPredict software., We are grateful to all participants. We would also like to thank the Instituto de Salud Carlos III, the Spanish Ministry of Science, Innovation, and Universities, the European Regional Development Fund (ERDF/FEDER), European Social Fund, “Investing in your future”, “A way of making Europe” (projects: PI08/0208, PI11/00325, PI14/00292, PI14/00612, PI14/01148, PI14/01151, PI17/00481, PI17/01997, PI18/01055, PI19/00394, PI19/00766, PI20/00721, PI20/01342, and PI21/00713; contracts: CP14/00041, JR19/00024, CPII19/00009, and CD20/00177); CERCA Program; Catalan Government, the Secretariat of Universities and Research of the Department of Enterprise and Knowledge (2017SGR01271, 2017SGR1355, and 2017SGR1365); Institut de Neurociències, Universitat de Barcelona; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2); the University of the Basque Country (2019 321218ELCY GIC18/107); the Basque Government (2017111104); European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña. The funding organizations played no role in the study design, data collection, analysis, or manuscript approval.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia

  • Andreu-Bernabeu, Álvaro
  • Díaz-Caneja, Covadonga M.
  • Costas, Javier
  • De Hoyos, Lucía
  • Stella, Carol
  • Gurriarán, Xaquín
  • Alloza, Clara
  • Fañanás Saura, Lourdes
  • Bobes García, Julio
  • González-Pinto, Ana
  • Crespo-Facorro, Benedicto
  • Martorell, Lourdes
  • Vilella, Elisabet
  • Muntané, Gerard
  • Nacher, Juan
  • Moltó, M. Dolors
  • Aguilar, Eduardo Jesús
  • Parellada, Mara
  • Arango López, Celso
  • González-Peñas, Javier
Previous research suggests an association of loneliness and social isolation (LNL-ISO) with schizophrenia. Here, we demonstrate a LNL-ISO polygenic score contribution to schizophrenia risk in an independent case-control sample (N = 3,488). We then subset schizophrenia predisposing variation based on its effect on LNL-ISO. We find that genetic variation with concordant effects in both phenotypes shows significant SNP-based heritability enrichment, higher polygenic contribution in females, and positive covariance with mental disorders such as depression, anxiety, attention-deficit hyperactivity disorder, alcohol dependence, and autism. Conversely, genetic variation with discordant effects only contributes to schizophrenia risk in males and is negatively correlated with those disorders. Mendelian randomization analyses demonstrate a plausible bi-directional causal relationship between LNL-ISO and schizophrenia, with a greater effect of LNL-ISO liability on schizophrenia than vice versa. These results illustrate the genetic footprint of LNL-ISO on schizophrenia.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis

  • Molina García, Mariola
  • Fraguas, David
  • Del Rey Mejias, Angel
  • Mezquida Mateos, Gisela
  • Sánchez-Torres, Ana M.
  • Amoretti Guadall, Silvia
  • Lobo, Antonio
  • González-Pinto, Ana
  • Andreu-Bernabeu, Álvaro
  • Corripio, Iluminada
  • Vieta i Pascual, Eduard, 1963-
  • Baeza, Inmaculada, 1970-
  • Mané Santacana, Anna
  • Cuesta, Manuel J.
  • Serna Gómez, Elena de la
  • Payá, Beatriz
  • Zorrilla, Iñaki
  • Arango, Celso
  • Bernardo Arroyo, Miquel
  • Rapado-Castro, Marta
  • Parellada, Mara
  • PEPs Group
Background: premorbid IQ (pIQ) and age of onset are predictors of clinical severity and long-term functioning after a first episode of psychosis. However, the additive influence of these variables on clinical, functional, and recovery rates outcomes is largely unknown. Methods: we characterized 255 individuals who have experienced a first episode of psychosis in four a priori defined subgroups based on pIQ (low pIQ < 85; average pIQ ≥ 85) and age of onset (early onset < 18 years; adult onset ≥ 18 years). We conducted clinical and functional assessments at baseline and at two-year follow-up. We calculated symptom remission and recovery rates using the Positive and Negative Symptoms of Schizophrenia Schedule (PANSS) and the Global Assessment Functioning (GAF or Children-GAF). We examined clinical and functional changes with pair-wise comparisons and two-way mixed ANOVA. We built hierarchical lineal and logistic regression models to estimate the predictive value of the independent variables over functioning or recovery rates. Results: early-onset patients had more severe positive symptoms and poorer functioning than adult-onset patients. At two-year follow-up, only early-onset with low pIQ and adult-onset with average pIQ subgroups differed consistently, with the former having more negative symptoms (d = 0.59), poorer functioning (d = 0.82), lower remission (61% vs. 81.1%), and clinical recovery (34.1% vs. 62.2%). Conclusions: early-onset individuals with low pIQ may present persistent negative symptoms, lower functioning, and less recovery likelihood at two-year follow-up. Intensive cognitive and functional programs for these individuals merit testing to improve long-term recovery rates in this subgroup.
Docta Complutense
Publication Artículo científico (JournalArticle)

Episignatures Stratifying Helsmoortel-Van Der Aa Syndrome Show Modest Correlation with Phenotype

  • Breen, Michael S.
  • Moreno Ruiz, María del Carmen
  • Parellada Redondo, María José
  • De Rubeis, Silvia
Helsmoortel-Van der Aa syndrome (HVDAS) is a neurodevelopmental condition associated with intellectual disability/developmental delay, autism spectrum disorder, and multiple medical comorbidities. HVDAS is caused by mutations in activity-dependent neuroprotective protein (ADNP). A recent study identified genome-wide DNA methylation changes in 22 individuals with HVDAS, adding to the group of neurodevelopmental disorders with an epigenetic signature. This methylation signature segregated those with HVDAS into two groups based on the location of the mutations. Here, we conducted an independent study on 24 individuals with HVDAS and replicated the existence of the two mutation-dependent episignatures. To probe whether the two distinct episignatures correlate with clinical outcomes, we used deep behavioral and neurobiological data from two prospective cohorts of individuals with a genetic diagnosis of HVDAS. We found limited phenotypic differences between the two HVDAS-affected groups and no evidence that individuals with more widespread methylation changes are more severely affected. Moreover, in spite of the methylation changes, we observed no profound alterations in the blood transcriptome of individuals with HVDAS. Our data warrant caution in harnessing methylation signatures in HVDAS as a tool for clinical stratification, at least with regard to behavioral phenotypes.
Dipòsit Digital de Documents de la UAB
Publication

Face individual identity recognition, a potential endophenotype in autism

  • Minio-Paluello, Ilaria|||0000-0002-9197-9749
  • Porciello, Giuseppina
  • Pascual Leone, Álvaro|||0000-0001-8975-0382
  • Baron-Cohen, Simon
Face individual identity recognition skill is heritable and independent of intellectual ability. Difficulties in face individual identity recognition are present in autistic individuals and their family members and are possibly linked to oxytocin polymorphisms in families with an autistic child. While it is reported that developmental prosopagnosia (i.e., impaired face identity recognition) occurs in 2-3% of the general population, no prosopagnosia prevalence estimate is available for autism. Furthermore, an autism within-group approach has not been reported towards characterizing impaired face memory and to investigate its possible links to social and communication difficulties. The present study estimated the prevalence of prosopagnosia in 80 autistic adults with no intellectual disability, investigated its cognitive characteristics and links to autism symptoms' severity, personality traits, and mental state understanding from the eye region by using standardized tests and questionnaires. More than one third of autistic participants showed prosopagnosia. Their face memory skill was not associated with their symptom's severity, empathy, alexithymia, or general intelligence. Face identity recognition was instead linked to mental state recognition from the eye region only in autistic individuals who had prosopagnosia, and this relationship did not depend on participants' basic face perception skills. Importantly, we found that autistic participants were not aware of their face memory skills. We did not test an epidemiological sample, and additional work is necessary to establish whether these results generalize to the entire autism spectrum. Impaired face individual identity recognition meets the criteria to be a potential endophenotype in autism. In the future, testing for face memory could be used to stratify autistic individuals into genetically meaningful subgroups and be translatable to autism animal models.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Genetic and psychosocial stressors have independent effects on the level of subclinical psychosis: findings from the multinational EU-GEI study

  • Pignon, B.
  • Peyre, H.
  • Ayrolles, A.
  • Bobes, Julio|||0000-0003-2187-4033
the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI) and FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS) (...), Pignon B, Peyre H, Ayrolles A, Kirkbride JB, Jamain S, Ferchiou A, Richard JR, Baudin G, Tosato S, Jongsma H, de Haan L, Tarricone I, Bernardo M, Velthorst E, Braca M, Arango C, Arrojo M, Bobes J, Del-Ben CM, Di Forti M, Gayer-Anderson C, Jones PB, La Cascia C, Lasalvia A, Menezes PR, Quattrone D, Sanjuán J, Selten JP, Tortelli A, Llorca PM, van Os J, Rutten BPF, Murray RM, Morgan C, Leboyer M, Szöke A, Schürhoff F
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: results from the EUGEI study

  • Fusar Poli, L.
  • Prachason, T.
  • Erzin, G.
  • Bobes, Julio|||0000-0003-2187-4033
  • Saiz Martínez, Pilar Alejandra
  • García-Portilla González, María Paz|||0000-0003-3643-1622
  • Outcome of Psychosis (GROUP)
The EUGEI project was supported by the grant agreement HEALTHF2-2010-241909 from the European Community’s Seventh Framework Programme. Dr Arango was supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, financed by the European Union - NextGenerationEU (PMP21/00051), PI19/01024. CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz. Drs. Bobes, García-Portilla, and Sáiz have received partial support from the Government of the Principality of Asturias PCTI-2021-2023 IDI/2021/111, the Fundación para la Investigación e Innovación Biosanitaria del Principado de Asturias (FINBA), and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, and Ministerio de Ciencia e Innovacion (...), Fusar-Poli, L., Prachason, T., Erzin, G., Pries, L.-K., Brondino, N., Politi, P., Delespaul, P., Kenis, G., Luykx, J.J., Lin, B.D., Richards, A.L., Akdede, B., Binbay, T., Altınyazar, V., Yalınçetin, B., Gümüş-Akay, G., Cihan, B., Soygür, H., Ulaş, H., Cankurtaran, E.Ş., Kaymak, S.U., Mihaljevic, M.M., Andric-Petrovic, S., Mirjanic, T., Bernardo, M., Mezquida, G., Amoretti, S., Bobes, J., Saiz, P.A., García-Portilla, M.P., Sanjuan, J., Escarti, M.J., Santos, J.L., Jiménez-López, E., Arrojo, M., Carracedo, A., López, G., González-Peñas, J., Parellada, M., Maric, N.P., Atbaşoğlu, C., Üçok, A., Alptekin, K., Saka, M.C., Arango, C., O'Donovan, M., van Os, J., Rutten, B.P., Guloksuz, S., Genetic Risk and Outcome of Psychosis (GROUP) investigators
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis

  • Solanes, A.
  • Mezquida, G.
  • Janssen, J.
  • Amoretti, S.
  • Bobes, Julio|||0000-0003-2187-4033
  • García-Portilla González, María Paz|||0000-0003-3643-1622
  • PEPs Group
We are grateful to all participants. We would also like to thank the Instituto de Salud Carlos III, the Spanish Ministry of Science, Innovation, and Universities, the European Regional Development Fund (ERDF/FEDER), European Social Fund, “Investing in your future”, “A way of making Europe” (projects: PI08/0208, PI11/00325, PI14/00292, PI14/ 00612, PI14/01148, PI14/01151, PI17/00481, PI17/01997, PI18/01055, PI19/00394, PI19/00766, PI20/00721, PI20/01342, and PI21/00713; contracts: CP14/00041, JR19/ 00024, CPII19/00009, and CD20/00177); CERCA Program; Catalan Government, the Secretariat of Universities and Research of the Department of Enterprise and Knowledge (2017SGR01271, 2017SGR1355, and 2017SGR1365); Institut de Neurociències, Universitat de Barcelona; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2); the University of the Basque Country (2019 321218ELCY GIC18/107); the Basque Government (2017111104); European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS) (...), Solanes A, Mezquida G, Janssen J, Amoretti S, Lobo A, González-Pinto A, Arango C, Vieta E, Castro-Fornieles J, Bergé D, Albacete A, Giné E, Parellada M, Bernardo M; PEPs group (collaborators); Pomarol-Clotet E, Radua J
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case-control study

  • Trotta, Giulia
  • Rodríguez, Victoria
  • Quattrone, Diego
  • Bobes, Julio|||0000-0003-2187-4033
  • EU-GEI WP2
The research leading to these results has received funding from the European Community's Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI). C. A. was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM. European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS)..., Trotta, G; Rodriguez, V; Quattrone, D; Spinazzola, E; Tripoli, G; Gayer-Anderson, C; Freeman, TP; Jongsma, HE; Sideli, L; Aas, M; Stilo, SA; La Cascia, C; Ferraro, L; La Barbera, D; Lasalvia, A; Tosato, S; Tarricone, I; D'Andrea, G; Tortelli, A; Schürhoff, F; Szöke, A; Pignon, B; Selten, JP; Velthorst, E; de Haan, L; Llorca, PM; Menezes, PR; Del Ben, CM; Santos, JL; Arrojo, M; Bobes, J; Sanjuán, J; Bernardo, M; Arango, C; Kirkbride, JB; Jones, PB; Richards, A; Rutten, BP; Van Os, J; Austin-Zimmerman, I; Li, ZK; Morgan, C; Sham, PC; Vassos, E; Wong, C; Bentall, R; Fisher, HL; Murray, RM; Alameda, L; Di Forti, M Trotta, Giulia; Rodriguez, Victoria; Quattrone, Diego; Spinazzola, Edoardo; Tripoli, Giada; Gayer- Anderson, Charlotte; Freeman, Tom P.; Jongsma, Hannah E.; Sideli, Lucia; Aas, Monica; Stilo, Simona A.; La Cascia, Caterina; Ferraro, Laura; La Barbera, Daniele; Lasalvia, Antonio; Tosato, Sarah; Tarricone, Ilaria; D'Andrea, Giuseppe; Tortelli, Andrea; Schuerhoff, Franck; Szoeke, Andrei; Pignon, Baptiste; Selten, Jean-Paul; Velthorst, Eva; de Haan, Lieuwe; Llorca, Pierre-Michel; Rossi Menezes, Paulo; Del Ben, Cristina M.; Luis Santos, Jose; Arrojo, Manuel; Bobes, Julio; Sanjuan, Julio; Bernardo, Miquel; Arango, Celso; Kirkbride, James B.; Jones, Peter B.; Richards, Alexander; Rutten, Bart P.; Van Os, Jim; Austin- Zimmerman, Isabelle; Li, Zhikun; Morgan, Craig; Sham, Pak C.; Vassos, Evangelos; Wong, Chloe; Bentall, Richard; Fisher, Helen L.; Murray, Robin M.; Alameda, Luis; Di Forti, Marta, EU GEI WP2 Group
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Recent natural selection conferred protection against schizophrenia by non-antagonistic pleiotropy

  • González Peñas, J.
  • Hoyos, Lucía de
  • Díaz Caneja, C. M.
  • Bobes, Julio|||0000-0003-2187-4033
This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, PI20/00721), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña. J González-Peñas holds a Sara Borrel from Instituto de Salud Carlos III (CD20/00118). C. M. Díaz-Caneja holds a Juan Rodés Grant from Instituto de Salud Carlos III (JR19/00024)
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia

  • Andreu Bernabeu, Á.
  • Díaz Caneja, C. M.
  • Costas, J.
  • De Hoyos, L.
  • Stella, C.
  • Gurriarán, X.
  • Alloza, C.
  • Fañanás, L.
  • Bobes, Julio|||0000-0003-2187-4033
This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, PI20/00721), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN), and FP7- HEALTH-2013-2.2.1-2- 602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz, and Fundación Mutua Madrileña. We are grateful to Paloma Pantoja for her assistance in the design of the figures. A.A.-B. holds a Rio Hortega Grant from Instituto de Salud Carlos III (CM20/00114). C.M.D.-C. holds a Juan Rodés Grant from Instituto de Salud Carlos III (JR19/00024)., Andreu-Bernabeu, Á., Díaz-Caneja, C.M., Costas, J., De Hoyos, L., Stella, C., Gurriarán, X., Alloza, C., Fañanás, L., Bobes, J., González-Pinto, A., Crespo-Facorro, B., Martorell, L., Vilella, E., Muntané, G., Nacher, J., Molto, M.D., Aguilar, E.J., Parellada, M., Arango, C., González-Peñas, J.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

The role of social deprivation and cannabis use in explaining variation in the incidence of psychotic disorders: findings from the EU-GEI study

  • Brink, Vera
  • Andleeb, Humma
  • Gayer Anderson, Charlotte
  • Bobes, Julio|||0000-0003-2187-4033
This work was supported by the European Community’s Seventh Framework Program (HEALTH-F2-2010-241909 [Project EU-GEI]) and the São Paulo Research Foundation (2012/0417-0). C.A. was supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), the European Union, ERDF Funds from the European Commission, “A way of making Europe,” financed by the European Union—NextGenerationEU (PMP21/00051), PI19/01024. CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (101034377), Project AIMS-2-TRIALS (777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health (award numbers 1U01MH124639-01 [Project ProNET], 5P50MH115846-03 [project FEP-CAUSAL]), Fundación Familia Alonso, and Fundación Alicia Koplowitz. (...), Brink V., Andleeb H., Gayer-Anderson C., Arango C., Arrojo M., Berardi D., Bernardo M., Bobes J., Del-Ben C.M., Ferraro L., De Haan L., La Barbera D., La Cascia C., Lasalvia A., Llorca P.-M., Menezes P.R., Pignon B., Sanjuán J., Santos J.L., Selten J.-P., Tarricone I., Tortelli A., Tripoli G., Velthorst E., Rutten B.P.F., Van Os J., Quattrone D., Murray R.M., Jones P.B., Morgan C., Di Forti M., Jongsma H.E., Kirkbride J.B.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Schizophrenia risk conferred by rare protein-truncating variants is conserved across diverse human populations

  • Liu, D.
  • Meyer, D.
  • Fennessy, B.
  • Bobes, Julio|||0000-0003-2187-4033
European Union Horizon 2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement number 115916 (Project PRISM) and grant agreement number 777394 (Project AIMS-2-TRIALS)), Fundación Familia Alonso and Fundación Alicia Koplowitz. We acknowledge the Biobanc of Parc Sanitari Sant Joan de Déu and Centro de Investigación Biomédica en Red de Salud Mental for samples and data procurement. J.G.-P. holds a Sara Borrell grant from Instituto de Salud Carlos III (CD20/00118). B.R. has received support from the Spanish Ministry of Science and Innovation Instituto de Salud Carlos III (PI18/00213 and Miguel Servet grants CPII21/00008 and MS16/00153), cofinanced by European Regional Development Fund Funds from the European Commission (...), Liu D, Meyer D, Fennessy B, Feng C, Cheng E, Johnson JS, Park YJ, Rieder MK, Ascolillo S, de Pins A, Dobbyn A, Lebovitch D, Moya E, Nguyen TH, Wilkins L, Hassan A; Psychiatric Genomics Consortium Phase 3 Targeted Sequencing of Schizophrenia Study Team; Burdick KE, Buxbaum JD, Domenici E, Frangou S, Hartmann AM, Laurent-Levinson C, Malhotra D, Pato CN, Pato MT, Ressler K, Roussos P, Rujescu D, Arango C, Bertolino A, Blasi G, Bocchio-Chiavetto L, Campion D, Carr V, Fullerton JM, Gennarelli M, González-Peñas J, Levinson DF, Mowry B, Nimgaokar VL, Pergola G, Rampino A, Cervilla JA, Rivera M, Schwab SG, Wildenauer DB, Daly M, Neale B, Singh T, O'Donovan MC, Owen MJ, Walters JT, Ayub M, Malhotra AK, Lencz T, Sullivan PF, Sklar P, Stahl EA, Huckins LM, Charney AW
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the eu-gei case-control and uk biobank studies

  • Austin Zimmerman, I.
  • Spinazzola, E.
  • Quattrone, D.
  • Bobes, Julio|||0000-0003-2187-4033
The EU-GEI project was funded by the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2009-241909 (Project EU-GEI). Dr Arango receives support from the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, ‘A way of making Europe’, financed by the European Union – NextGenerationEU (PMP21/00051), PI19/01024. CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (grant agreement No. 101034377), Project AIMS-2-TRIALS (grant agreement No. 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz (...), Austin-Zimmerman I., Spinazzola E., Quattrone D., Wu-Choi B., Trotta G., Li Z., Johnson E., Richards A.L., Freeman T.P., Tripoli G., Gayer-Anderson C., Rodriguez V., Jongsma H.E., Ferraro L., La Cascia C., Tosato S., Tarricone I., Berardi D., Bonora E., Seri M., D'Andrea G., Szöke A., Arango C., Bobes J., Sanjuán J., Santos J.L., Arrojo M., Velthorst E., Bernardo M., Del-Ben C.M., Rossi Menezes P., Selten J.-P., Jones P.B., Kirkbride J.B., Rutten B.P.F., Tortelli A., Llorca P.-M., De Haan L., Stilo S., La Barbera D., Lasalvia A., Schurnhoff F., Pignon B., Van Os J., Lynskey M., Morgan C., O' Donovan M., Lewis C.M., Sham P.C., Murray R.M., Vassos E., Di Forti M.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

The role of premorbid IQ and age of onset as useful predictors of clinical, functional outcomes, and recovery of individuals with a first episode of psychosis

  • Molina-García, Mariola
  • Fraguas, David
  • Rey-Mejías, Ángel del
  • Mezquida, Gisela
  • Sánchez Torres, Ana María
  • Amoretti, Silvia
  • Lobo, Antonio
  • González Pinto, Ana
  • Andreu-Bernabeu, Álvaro
  • Corripio, Iluminada
  • Vieta, Eduard
  • Baeza, Inmaculada
  • Mané, Anna
  • Cuesta, Manuel J.
  • Serna, Elena de la
  • Payá, Beatriz
  • Zorrilla, Iñaki
  • Arango, Celso
  • Bernardo, Miguel
  • Rapado-Castro, Marta
  • Parellada, Mara
  • PEPs Group
Background: premorbid IQ (pIQ) and age of onset are predictors of clinical severity and long-term functioning after a first episode of psychosis. However, the additive influence of these variables on clinical, functional, and recovery rates outcomes is largely unknown. Methods: we characterized 255 individuals who have experienced a first episode of psychosis in four a priori defined subgroups based on pIQ (low pIQ < 85; average pIQ ≥ 85) and age of onset (early onset < 18 years; adult onset ≥ 18 years). We conducted clinical and functional assessments at baseline and at two-year follow-up. We calculated symptom remission and recovery rates using the Positive and Negative Symptoms of Schizophrenia Schedule (PANSS) and the Global Assessment Functioning (GAF or Children-GAF). We examined clinical and functional changes with pair-wise comparisons and two-way mixed ANOVA. We built hierarchical lineal and logistic regression models to estimate the predictive value of the independent variables over functioning or recovery rates. Results: early-onset patients had more severe positive symptoms and poorer functioning than adult-onset patients. At two-year follow-up, only early-onset with low pIQ and adult-onset with average pIQ subgroups differed consistently, with the former having more negative symptoms (d = 0.59), poorer functioning (d = 0.82), lower remission (61% vs. 81.1%), and clinical recovery (34.1% vs. 62.2%). Conclusions: early-onset individuals with low pIQ may present persistent negative symptoms, lower functioning, and less recovery likelihood at two-year follow-up. Intensive cognitive and functional programs for these individuals merit testing to improve long-term recovery rates in this subgroup., This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III, PI02/1248, PI03032, PI05/0678, PI08/0208 PI09/01442, PI11/00325, PI12/1303, PI14/00612, PI15/00723, PI17/009977, PI18/00753 cofinanced by ERDF Funds from the European Commission, 'A way of making Europe', CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2). The CERCA Program/Generalitat de Catalunya And Secretaria d'Universitats i Recerca del Departament d'Economia I Coneixement (2017SGR1355). Departament de Salut de la Generalitat de Catalunya, en la convocatoria corresponent a l'any 2017 de concessió de subvencions del Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020, modalitat Projectes de recerca orientats a l'atenció primària, amb el codi d'expedient SLT006/17/00345. European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTi-MISE), FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña.